- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05564377
Gezielte, durch Gentests gesteuerte Therapie bei der Behandlung von Patienten mit lokal fortgeschrittenen oder fortgeschrittenen soliden Tumoren, die ComboMATCH-Registrierungsstudie
Molekulare Analyse für die Wahl der Kombinationstherapie (ComboMATCH)
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.
Studienübersicht
Status
Bedingungen
- Anatomischer Brustkrebs im Stadium III AJCC v8
- Rezidivierendes Eileiterkarzinom
- Rezidivierendes Ovarialkarzinom
- Rezidivierendes primäres Peritonealkarzinom
- Anatomischer Brustkrebs im Stadium IV AJCC v8
- Fortgeschrittenes bösartiges solides Neoplasma
- Lokal fortgeschrittenes bösartiges solides Neoplasma
- Nicht resezierbares bösartiges festes Neoplasma
- Rezidivierendes Endometriumkarzinom
- Rezidivierende bösartige solide Neubildung
- Metastasierendes bösartiges festes Neoplasma
- Bösartige Neubildung des weiblichen Fortpflanzungssystems
- Rezidivierende bösartige Neubildung des weiblichen Fortpflanzungssystems
- Metastasiertes HER2-negatives Mammakarzinom
- Inoperables HER2-negatives Brustkarzinom
Intervention / Behandlung
- Arzneimittel: Fluorouracil
- Verfahren: Bone Marrow Biopsy
- Verfahren: Computed Tomography
- Verfahren: Magnetic Resonance Imaging
- Verfahren: Echocardiography Test
- Verfahren: Multigated Acquisition Scan
- Verfahren: Biopsy Procedure
- Verfahren: Positron Emission Tomography
- Verfahren: Bone Marrow Aspiration
- Arzneimittel: Olaparib
- Arzneimittel: Binimetinib
- Arzneimittel: Palbociclib
- Arzneimittel: Ipatasertib
- Arzneimittel: Fulvestrant
- Biologisch: Panitumumab
- Arzneimittel: Oxaliplatin
- Arzneimittel: Leucovorin
- Verfahren: Bone Scan
- Verfahren: Biospecimen Collection
- Arzneimittel: Neratinib Maleate
- Arzneimittel: Alpelisib
- Arzneimittel: Nilotinib Hydrochloride Monohydrate
- Arzneimittel: Paclitaxel
- Arzneimittel: Sotorasib
- Verfahren: Mutation Carrier Screening
- Arzneimittel: Selumetinib Sulfate
Detaillierte Beschreibung
PRIMARY OBJECTIVE:
I. To register, allocate, and assign patients to ComboMATCH treatment trials.
SECONDARY OBJECTIVES:
I. To evaluate the rate of positive outcomes in defined cohorts within treatment trials of treatment combinations including targeted therapies for molecularly defined populations, and also in the subset of treatment trials where the treatments are supported by in vivo models.
II. To perform quality control of the patients registered in the form of pathological confirmation of disease and sub-type to confirm diagnosis and treatment arm allocation.
SECONDARY CORRELATIVE OBJECTIVES:
I. Assess the concordance of the central molecular characterization of the pre-treatment biopsy samples with the genetic readouts from the Designated Laboratories (DLs) for patients enrolled on the ComboMATCH treatment trials.
II. To assess how the registration diagnostic tumor mutation profile and pre-treatment biopsy profile compare to the circulating tumor-derived deoxyribonucleic acid (ctDNA) mutation profile from plasma.
EXPLORATORY OBJECTIVE:
I. Assess association between ComboMATCH treatment trials outcomes (positive or negative) with the type of rationale for the selected drug combinations and the type of rationale for the gene variant/combination for selection (e.g., whether the trial was based on targeted therapies for molecularly defined populations, those that were supported by in vivo models, and those that were supported by empiric clinical data).
OUTLINE:
REGISTRATION: Patients undergo tumor mutational screening of previously-collected tumor samples for specific, pre-defined mutations, amplifications, or translocations of interest via tumor sequencing. Patients who are 18 years or older and have biopsiable disease undergo a new biopsy for research purposes prior to initiating treatment on the ComboMATCH treatment trial.
TREATMENT: Patients with mutations targeted to investigational combination therapies are assigned to 1 of 20 treatment subprotocols.
EAY191-N4: Patients with RAS pathway mutant ovarian or endometrial cancer are randomized to 1 of 2 arms.
ARM I: Patients receive selumetinib orally (PO) twice daily (BID) and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as echocardiogram (ECHO) or multigated acquisition (MUGA), and computed tomography (CT) scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated.
ARM II: Patients receive selumetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience progression may elect to cross over to Arm I provided they have not had dose limiting toxicities to monotherapy selumetinib. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as ECHO or MUGA, and CT scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated.
EAY191-N2: Patients with inactivating or inferred inactivating NF1 alterations, and hormone receptor positive, HER2-negative metastatic breast cancer. Patients who are fulvestrant naive are assigned to Cohort I, while patients who are fulvestrant resistant are assigned to Cohort II.
COHORT I: Patients are randomized to 1 of 2 arms.
ARM I:Patients receive fulvestrant intramuscularly (IM) on day 1 and day 15 of cycle 1 and day 1 of subsequent cycles and binimetinib PO BID on days 15 to 28 of cycle 1 and day 1 through 28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT, magnetic resonance imaging (MRI), or bone scan, ECHO or MUGA, and tumor biopsy, as well as possible blood sample collection during screening and on study.
ARM II: Patients receive fulvestrant IM on day 1 and day 15 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who progress on fulvestrant alone may migrate to cohort II if they meet the migration eligibility criteria. Patients not willing to migrate to cohort II will have further therapy at the investigator's discretion. Patients undergo a CT, MRI, or bone scan and tumor biopsy, as well as ECHO or MUGA and possible blood sample collection during screening and on study.
COHORT II: Patients receive fulvestrant IM on day 1 of each cycle and binimetinib PO BID on days 15-28 of cycle 1 and day 1 through 28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT, MRI, or bone scan, ECHO or MUGA and tumor biopsy, as well as possible blood sample collection during screening and on study.
EAY191-E4: Patients with solid tumors who previously underwent taxane therapy.
Patients receive nilotinib hydrochloride monohydrate PO BID on days 1-28 and paclitaxel intravenously (IV) over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI during screening or cycle 1 day 1, every 2 cycles for 1 year, every 3 cycles for patients on study for more than 1 year, and every 4 cycles for patients on study for more than 3 years and may also undergo CT or MRI during follow-up every 3 months for 2 years and then every 6 months for 1 year if clinically indicated. Patients also undergo collection of blood samples at baseline, cycle 2 day 1, and optionally at progression as well as tumor biopsy at baseline and optionally at progression.
EAY191-A3: Patients with KRAS/NRAS/BRAF mutated low-grade serous ovarian cancer (LGSOC) naive to MEK or CDK4/6 inhibitor therapy are randomized to either combination cohort 1 or monotherapy cohort 1. Patients with LGSOC who have received prior MEK inhibitor therapy are assigned to combination cohort 2. Patients with KRAS/NRAS/HRAS/non-V600E BRAF mutated pancreatic cancer are assigned to combination cohort 3. Patients with all other KRAS/NRAS/HRAS mutated tumor types (excluding LGSOC, non-small cell lung cancer, colorectal cancer, pancreatic, and melanoma) are assigned to combination cohort 4.
COMBINATION COHORTS 1, 2, 3, 4: Patients receive palbociclib PO and binimetinib PO throughout the trial. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/or during follow up.
MONOTHERAPY COHORT 1: Patients receive binimetinib PO throughout the trial. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/or during follow up.
EAY191-S3: Patients with an activating AKT mutation solid tumor.
Patients receive paclitaxel IV on days 1, 8, and 15 and ipatasertib PO on days 1-21 of each cycle. Treatment repeats every 28 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI and blood collection throughout the trial. Patients also undergo a tumor biopsy during screening and optionally during follow-up.
EAY191-A6: Patients with RAS/RAF/MEK/ERK mutant biliary tract cancers are randomized to 1 of 2 arms.
ARM 1: Patients receive leucovorin IV, oxaliplatin IV, and fluorouracil IV on study. Patients undergo echocardiogram (ECHO) and multigated acquisition scan (MUGA) during screening and on study, a CT with contrast, MRI, or a fludeoxyglucose F-18 positron emission tomography (FDG-PET) during screening, collection of blood during screening and on study, and a biopsy during screening. Patients may also undergo brain MRI or CT during screening and on study, bone scans on study, and biopsy on study if clinically indicated.
ARM 2: Patients receive binimetinib PO, leucovorin IV, oxaliplatin IV, and fluorouracil IV on study. Patients undergo ECHO and MUGA during screening and on study, a CT with contrast, MRI, or an FDG-PET during screening, collection of blood during screening and on study, and a biopsy during screening. Patients may also undergo brain MRI or CT during screening and on study, bone scans on study, and biopsy on study if clinically indicated.
EAY191-E5: Patients are assigned to 1 of 2 cohorts.
COHORT I: Patients who have never received a KRAS G12C inhibitor are randomized to arms A or B.
ARM A: Patients receive sotorasib PO once daily (QD) on days 1-28 and panitumumab intravenously IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study.
ARM B: Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study.
COHORT II: Patients who have received a KRAS G12C inhibitor are assigned to arm C.
ARM C: Patients receive combination therapy as in Arm A.
EAY191-A2: Patients are assigned to 1 of 3 cohorts.
COHORT 1: PARP-inhibitor naive patients are assigned to Arm A.
ARM A: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.
COHORT 2: PARP-inhibitor naive patients are randomized to 1 of 2 arms.
ARM B: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.
ARM C: Patients receive olaparib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients experiencing disease progression have the option to migrate to Cohort 3, Arm D. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.
COHORT 3: PARP-inhibitor resistant patients are assigned to Arm D.
ARM D: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.
EAY191-N5: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive neratinib maleate PO QD on days 1-14 of cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then receive neratinib maleate PO QD on days 1-28 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience progression may crossover to Arm II. Patients undergo ECHO or MUGA during screening and on study, and CT or MRI and collection of blood samples throughout the trial. Patients may also undergo tumor biopsy during screening and on study.
ARM II: Patients receive neratinib maleate PO QD on days 1-14 of cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then receive neratinib maleate PO QD on days 1-28 and palbociclib PO QD on days 1-21 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening and on study, and CT or MRI and collection of blood samples throughout the trial. Patients may also undergo tumor biopsy during screening and on study.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
-
Bayamón, Puerto Rico, 00961
- Rekrutierung
- Puerto Rico Hematology Oncology Group
-
Hauptermittler:
- Luis J. Santos Reyes
-
Kontakt:
- Site Public Contact
- Telefonnummer: 787-780-2865
-
Manati, Puerto Rico, 00674
- Rekrutierung
- Doctors Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 787-621-4397
-
Hauptermittler:
- Luis J. Santos Reyes
-
San Juan, Puerto Rico, 00927
- Rekrutierung
- Centro Comprensivo de Cancer de UPR
-
Hauptermittler:
- Luis J. Santos Reyes
-
Kontakt:
- Site Public Contact
- E-Mail: ecog.rss@jimmy.harvard.edu
-
San Juan, Puerto Rico, 00927
- Rekrutierung
- PROncology
-
Hauptermittler:
- Luis J. Santos Reyes
-
Kontakt:
- Site Public Contact
- Telefonnummer: 787-919-7919
- E-Mail: info@PRoncology.com
-
-
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35233
- Rekrutierung
- University of Alabama at Birmingham Cancer Center
-
Hauptermittler:
- Rebecca C. Arend
-
Kontakt:
- Site Public Contact
- E-Mail: gingerreeves@uabmc.edu
-
Mobile, Alabama, Vereinigte Staaten, 36688
- Rekrutierung
- University of South Alabama Mitchell Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 251-445-9870
- E-Mail: pfrancisco@usouthal.edu
-
Hauptermittler:
- Ahmed Abdalla
-
-
Alaska
-
Anchorage, Alaska, Vereinigte Staaten, 99508
- Rekrutierung
- Alaska Women's Cancer Care
-
Kontakt:
- Site Public Contact
- Telefonnummer: 907-212-6871
- E-Mail: AKPAMC.OncologyResearchSupport@providence.org
-
Hauptermittler:
- Alison K. Conlin
-
-
Arizona
-
Goodyear, Arizona, Vereinigte Staaten, 85338
- Rekrutierung
- CTCA at Western Regional Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 623-207-3000
-
Hauptermittler:
- Sagun Shrestha
-
Kingman, Arizona, Vereinigte Staaten, 86401
- Rekrutierung
- Kingman Regional Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 702-384-0013
- E-Mail: research@sncrf.org
-
Hauptermittler:
- Khawaja S. Jahangir
-
Phoenix, Arizona, Vereinigte Staaten, 85054
- Suspendiert
- Mayo Clinic Hospital in Arizona
-
-
Arkansas
-
Jonesboro, Arkansas, Vereinigte Staaten, 72401
- Rekrutierung
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
-
Kontakt:
- Site Public Contact
- Telefonnummer: 870-936-7066
- E-Mail: Emily.Carvell@bmhcc.org
-
Hauptermittler:
- Andrew J. Benefield
-
-
California
-
Arroyo Grande, California, Vereinigte Staaten, 93420
- Rekrutierung
- PCR Oncology
-
Kontakt:
- Site Public Contact
- Telefonnummer: 702-384-0013
- E-Mail: research@sncrf.org
-
Hauptermittler:
- Khawaja S. Jahangir
-
Carmichael, California, Vereinigte Staaten, 95608
- Rekrutierung
- Mercy San Juan Medical Center
-
Hauptermittler:
- Loretta J. Nastoupil
-
Kontakt:
- Site Public Contact
- Telefonnummer: 720-874-1881
- E-Mail: ResearchInstituteInquiries@commonspirit.org
-
Carmichael, California, Vereinigte Staaten, 95608
- Rekrutierung
- Mercy Cancer Center - Carmichael
-
Hauptermittler:
- Loretta J. Nastoupil
-
Kontakt:
- Site Public Contact
- Telefonnummer: 720-874-1881
- E-Mail: ResearchInstituteInquiries@CommonSpirit.org
-
Dublin, California, Vereinigte Staaten, 94568
- Aktiv, nicht rekrutierend
- Epic Care-Dublin
-
Elk Grove, California, Vereinigte Staaten, 95758
- Rekrutierung
- Mercy Cancer Center - Elk Grove
-
Hauptermittler:
- Loretta J. Nastoupil
-
Kontakt:
- Site Public Contact
- Telefonnummer: 720-874-1881
- E-Mail: ResearchInstituteInquiries@CommonSpirit.org
-
Encinitas, California, Vereinigte Staaten, 92024
- Rekrutierung
- UC San Diego Health System - Encinitas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 760-536-7700
-
Hauptermittler:
- Peter Vu
-
La Jolla, California, Vereinigte Staaten, 92093
- Rekrutierung
- UC San Diego Moores Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 858-822-5354
- E-Mail: cancercto@ucsd.edu
-
Hauptermittler:
- Peter Vu
-
Los Angeles, California, Vereinigte Staaten, 90048
- Rekrutierung
- Cedars-Sinai Medical Center
-
Hauptermittler:
- Omid Hamid
-
Kontakt:
- Site Public Contact
- Telefonnummer: 310-423-2133
- E-Mail: Cancer.trial.info@cshs.org
-
Los Angeles, California, Vereinigte Staaten, 90025
- Rekrutierung
- The Angeles Clinic and Research Institute - West Los Angeles Office
-
Kontakt:
- Site Public Contact
- E-Mail: ecog.rss@jimmy.harvard.edu
-
Hauptermittler:
- Omid Hamid
-
Martinez, California, Vereinigte Staaten, 94553-3156
- Aktiv, nicht rekrutierend
- Contra Costa Regional Medical Center
-
Orange, California, Vereinigte Staaten, 92868
- Rekrutierung
- Children's Hospital of Orange County
-
Kontakt:
- Site Public Contact
- Telefonnummer: 714-509-8646
- E-Mail: oncresearch@choc.org
-
Hauptermittler:
- Elyssa M. Rubin
-
Orange, California, Vereinigte Staaten, 92868
- Rekrutierung
- Saint Joseph Hospital - Orange
-
Kontakt:
- Site Public Contact
- Telefonnummer: 714-734-6220
-
Hauptermittler:
- Timothy E. Byun
-
Palo Alto, California, Vereinigte Staaten, 94304
- Rekrutierung
- Stanford Cancer Institute Palo Alto
-
Hauptermittler:
- James M. Ford
-
Kontakt:
- Site Public Contact
- Telefonnummer: 650-498-7061
- E-Mail: cancertrialsinfo@stanford.edu
-
Palo Alto, California, Vereinigte Staaten, 94304
- Rekrutierung
- VA Palo Alto Health Care System
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-455-0057
-
Hauptermittler:
- Harlan A. Pinto
-
Rocklin, California, Vereinigte Staaten, 95765
- Rekrutierung
- Mercy Cancer Center - Rocklin
-
Hauptermittler:
- Loretta J. Nastoupil
-
Kontakt:
- Site Public Contact
- Telefonnummer: 720-874-1881
- E-Mail: ResearchInstituteInquiries@CommonSpirit.org
-
Sacramento, California, Vereinigte Staaten, 95816
- Rekrutierung
- Mercy Cancer Center - Sacramento
-
Hauptermittler:
- Loretta J. Nastoupil
-
Kontakt:
- Site Public Contact
- Telefonnummer: 720-874-1881
- E-Mail: ResearchInstituteInquiries@CommonSpirit.org
-
San Diego, California, Vereinigte Staaten, 92103
- Rekrutierung
- UC San Diego Medical Center - Hillcrest
-
Kontakt:
- Site Public Contact
- E-Mail: rhabbaba@health.ucsd.edu
-
Hauptermittler:
- Peter Vu
-
San Diego, California, Vereinigte Staaten, 92123
- Rekrutierung
- Sharp Memorial Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 858-939-5062
- E-Mail: cathy.wood@sharp.com
-
Hauptermittler:
- Charles H. Redfern
-
San Francisco, California, Vereinigte Staaten, 94158
- Suspendiert
- UCSF Medical Center-Mission Bay
-
Santa Monica, California, Vereinigte Staaten, 90404
- Rekrutierung
- Saint John's Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 310-582-7448
-
Hauptermittler:
- Reva K. Basho
-
Walnut Creek, California, Vereinigte Staaten, 94597
- Aktiv, nicht rekrutierend
- Epic Care Cyberknife Center
-
Whittier, California, Vereinigte Staaten, 90602
- Suspendiert
- Presbyterian Intercommunity Hospital
-
Woodland, California, Vereinigte Staaten, 95695
- Rekrutierung
- Woodland Memorial Hospital
-
Hauptermittler:
- Loretta J. Nastoupil
-
Kontakt:
- Site Public Contact
- Telefonnummer: 720-874-1881
- E-Mail: ResearchInstituteInquiries@CommonSpirit.org
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80045
- Rekrutierung
- UCHealth University of Colorado Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 720-848-0650
-
Hauptermittler:
- Bradley R. Corr
-
Fort Collins, Colorado, Vereinigte Staaten, 80524
- Rekrutierung
- Poudre Valley Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 970-297-6150
-
Hauptermittler:
- Bradley R. Corr
-
Fort Collins, Colorado, Vereinigte Staaten, 80528
- Rekrutierung
- Cancer Care and Hematology-Fort Collins
-
Kontakt:
- Site Public Contact
- E-Mail: ecog.rss@jimmy.harvard.edu
-
Hauptermittler:
- Bradley R. Corr
-
Greeley, Colorado, Vereinigte Staaten, 80631
- Rekrutierung
- UCHealth Greeley Hospital
-
Kontakt:
- Site Public Contact
- E-Mail: ecog.rss@jimmy.harvard.edu
-
Hauptermittler:
- Bradley R. Corr
-
Loveland, Colorado, Vereinigte Staaten, 80538
- Rekrutierung
- Medical Center of the Rockies
-
Kontakt:
- Site Public Contact
- Telefonnummer: 970-203-7083
-
Hauptermittler:
- Bradley R. Corr
-
-
Delaware
-
Newark, Delaware, Vereinigte Staaten, 19713
- Rekrutierung
- Helen F Graham Cancer Center
-
Hauptermittler:
- Gregory A. Masters
-
Kontakt:
- Site Public Contact
- Telefonnummer: 302-623-4450
- E-Mail: lbarone@christianacare.org
-
Newark, Delaware, Vereinigte Staaten, 19713
- Rekrutierung
- Medical Oncology Hematology Consultants PA
-
Hauptermittler:
- Gregory A. Masters
-
Kontakt:
- Site Public Contact
- Telefonnummer: 302-623-4450
- E-Mail: lbarone@christianacare.org
-
-
Florida
-
Aventura, Florida, Vereinigte Staaten, 33180
- Rekrutierung
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Kontakt:
- Site Public Contact
- Telefonnummer: 954-461-2180
-
Hauptermittler:
- Chukwuemeka (Emeka) V. Ikpeazu
-
Coral Gables, Florida, Vereinigte Staaten, 33146
- Rekrutierung
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Kontakt:
- Site Public Contact
- Telefonnummer: 305-243-2647
-
Hauptermittler:
- Chukwuemeka (Emeka) V. Ikpeazu
-
Deerfield Beach, Florida, Vereinigte Staaten, 33442
- Rekrutierung
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Kontakt:
- Site Public Contact
- Telefonnummer: 305-243-2647
-
Hauptermittler:
- Chukwuemeka (Emeka) V. Ikpeazu
-
Fort Lauderdale, Florida, Vereinigte Staaten, 33316
- Aktiv, nicht rekrutierend
- Broward Health Medical Center
-
Gainesville, Florida, Vereinigte Staaten, 32610
- Rekrutierung
- UF Health Cancer Institute - Gainesville
-
Kontakt:
- Site Public Contact
- Telefonnummer: 352-273-8010
- E-Mail: cancer-center@ufl.edu
-
Hauptermittler:
- Thomas J. George
-
Jacksonville, Florida, Vereinigte Staaten, 32224-9980
- Rekrutierung
- Mayo Clinic in Florida
-
Kontakt:
- Site Public Contact
- Telefonnummer: 855-776-0015
-
Hauptermittler:
- Aaron S. Mansfield
-
Miami, Florida, Vereinigte Staaten, 33136
- Rekrutierung
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 305-243-2647
-
Hauptermittler:
- Chukwuemeka (Emeka) V. Ikpeazu
-
Miami, Florida, Vereinigte Staaten, 33176
- Rekrutierung
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Kontakt:
- Site Public Contact
- Telefonnummer: 305-243-2647
-
Hauptermittler:
- Chukwuemeka (Emeka) V. Ikpeazu
-
North Miami, Florida, Vereinigte Staaten, 33181
- Rekrutierung
- University of Miami Sylvester Comprehensive Cancer Center at Sole Mia
-
Hauptermittler:
- Chukwuemeka (Emeka) V. Ikpeazu
-
Kontakt:
- Site Public Contact
- E-Mail: kginnity@med.miami.edu
-
Plantation, Florida, Vereinigte Staaten, 33324
- Rekrutierung
- UM Sylvester Comprehensive Cancer Center at Plantation
-
Kontakt:
- Site Public Contact
- Telefonnummer: 305-243-2647
-
Hauptermittler:
- Chukwuemeka (Emeka) V. Ikpeazu
-
-
Georgia
-
Newnan, Georgia, Vereinigte Staaten, 30265
- Aktiv, nicht rekrutierend
- CTCA at Southeastern Regional Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, Vereinigte Staaten, 96826
- Rekrutierung
- Kapiolani Medical Center for Women and Children
-
Hauptermittler:
- Jeffrey L. Berenberg
-
Kontakt:
- Site Public Contact
- Telefonnummer: 808-983-6090
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- Rekrutierung
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Hauptermittler:
- Jeffrey L. Berenberg
-
Kontakt:
- Site Public Contact
- Telefonnummer: 808-524-6115
- E-Mail: i.webster@hawaiicancercare.com
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- Rekrutierung
- Queen's Cancer Cenrer - POB I
-
Hauptermittler:
- Jeffrey L. Berenberg
-
Kontakt:
- Site Public Contact
- Telefonnummer: 808-532-0315
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- Rekrutierung
- Queen's Medical Center
-
Hauptermittler:
- Jeffrey L. Berenberg
-
Kontakt:
- Site Public Contact
- Telefonnummer: 808-545-8548
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- Rekrutierung
- Straub Clinic and Hospital
-
Hauptermittler:
- Jeffrey L. Berenberg
-
Kontakt:
- Site Public Contact
- Telefonnummer: 808-522-4333
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- Rekrutierung
- University of Hawaii Cancer Center
-
Hauptermittler:
- Jeffrey L. Berenberg
-
Kontakt:
- Site Public Contact
- Telefonnummer: 808-586-2979
-
Honolulu, Hawaii, Vereinigte Staaten, 96817
- Rekrutierung
- Queen's Cancer Center - Kuakini
-
Hauptermittler:
- Jeffrey L. Berenberg
-
Kontakt:
- Site Public Contact
- Telefonnummer: 808-531-8521
-
‘Aiea, Hawaii, Vereinigte Staaten, 96701
- Rekrutierung
- Hawaii Cancer Care - Westridge
-
Kontakt:
- Site Public Contact
- Telefonnummer: 808-539-2273
- E-Mail: info@hawaiicancercare.com
-
Hauptermittler:
- Jeffrey L. Berenberg
-
‘Aiea, Hawaii, Vereinigte Staaten, 96701
- Rekrutierung
- Pali Momi Medical Center
-
Hauptermittler:
- Jeffrey L. Berenberg
-
Kontakt:
- Site Public Contact
- Telefonnummer: 808-486-6000
-
‘Ewa Beach, Hawaii, Vereinigte Staaten, 96706
- Rekrutierung
- The Queen's Medical Center - West Oahu
-
Hauptermittler:
- Jeffrey L. Berenberg
-
Kontakt:
- Site Public Contact
- E-Mail: rohta@queens.org
-
-
Idaho
-
Boise, Idaho, Vereinigte Staaten, 83712
- Rekrutierung
- Saint Luke's Cancer Institute - Boise
-
Hauptermittler:
- Alison K. Conlin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 208-381-2774
- E-Mail: eslinget@slhs.org
-
Boise, Idaho, Vereinigte Staaten, 83706
- Rekrutierung
- Saint Alphonsus Cancer Care Center-Boise
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-3671
- E-Mail: stephanie.couch@stjoeshealth.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Caldwell, Idaho, Vereinigte Staaten, 83605
- Rekrutierung
- Saint Alphonsus Cancer Care Center-Caldwell
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-3671
- E-Mail: stephanie.couch@stjoeshealth.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Coeur d'Alene, Idaho, Vereinigte Staaten, 83814
- Rekrutierung
- Kootenai Health - Coeur d'Alene
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Fruitland, Idaho, Vereinigte Staaten, 83619
- Rekrutierung
- Saint Luke's Cancer Institute - Fruitland
-
Hauptermittler:
- Alison K. Conlin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 208-381-2774
- E-Mail: eslinget@slhs.org
-
Meridian, Idaho, Vereinigte Staaten, 83642
- Rekrutierung
- Saint Luke's Cancer Institute - Meridian
-
Hauptermittler:
- Alison K. Conlin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 208-381-2774
- E-Mail: eslinget@slhs.org
-
Nampa, Idaho, Vereinigte Staaten, 83687
- Rekrutierung
- Saint Luke's Cancer Institute - Nampa
-
Hauptermittler:
- Alison K. Conlin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 208-381-2774
- E-Mail: eslinget@slhs.org
-
Nampa, Idaho, Vereinigte Staaten, 83687
- Rekrutierung
- Saint Alphonsus Cancer Care Center-Nampa
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Post Falls, Idaho, Vereinigte Staaten, 83854
- Rekrutierung
- Kootenai Clinic Cancer Services - Post Falls
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Sandpoint, Idaho, Vereinigte Staaten, 83864
- Rekrutierung
- Kootenai Clinic Cancer Services - Sandpoint
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Twin Falls, Idaho, Vereinigte Staaten, 83301
- Rekrutierung
- Saint Luke's Cancer Institute - Twin Falls
-
Hauptermittler:
- Alison K. Conlin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 208-381-2774
- E-Mail: eslinget@slhs.org
-
-
Illinois
-
Barrington, Illinois, Vereinigte Staaten, 60010
- Rekrutierung
- Advocate Good Shepherd Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-842-4847
-
Hauptermittler:
- Antony Ruggeri
-
Bloomington, Illinois, Vereinigte Staaten, 61704
- Rekrutierung
- Illinois CancerCare-Bloomington
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Canton, Illinois, Vereinigte Staaten, 61520
- Rekrutierung
- Illinois CancerCare-Canton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Carterville, Illinois, Vereinigte Staaten, 62918
- Rekrutierung
- SIH Cancer Institute
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 618-985-3333
- E-Mail: clinical.research@sih.net
-
Carthage, Illinois, Vereinigte Staaten, 62321
- Rekrutierung
- Illinois CancerCare-Carthage
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Centralia, Illinois, Vereinigte Staaten, 62801
- Rekrutierung
- Centralia Oncology Clinic
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-Mail: morganthaler.jodi@mhsil.com
-
Chicago, Illinois, Vereinigte Staaten, 60637
- Rekrutierung
- University of Chicago Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 773-702-8222
- E-Mail: cancerclinicaltrials@bsd.uchicago.edu
-
Hauptermittler:
- Ardaman Shergill
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Rekrutierung
- Northwestern University
-
Hauptermittler:
- Devalingam Mahalingam
-
Kontakt:
- Site Public Contact
- Telefonnummer: 312-695-1301
- E-Mail: cancer@northwestern.edu
-
Chicago, Illinois, Vereinigte Staaten, 60612
- Rekrutierung
- University of Illinois
-
Kontakt:
- Site Public Contact
- Telefonnummer: 312-355-3046
-
Hauptermittler:
- Ryan Nguyen
-
Chicago, Illinois, Vereinigte Staaten, 60612
- Rekrutierung
- John H Stroger Jr Hospital of Cook County
-
Kontakt:
- Site Public Contact
- Telefonnummer: 312-864-5204
-
Hauptermittler:
- Deimante M. Tamkus
-
Chicago, Illinois, Vereinigte Staaten, 60657
- Rekrutierung
- Advocate Illinois Masonic Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 773-296-5360
-
Hauptermittler:
- Antony Ruggeri
-
Chicago, Illinois, Vereinigte Staaten, 60608
- Rekrutierung
- Mount Sinai Hospital Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 773-257-5960
- E-Mail: suhi@sinai.org
-
Hauptermittler:
- Pam G. Khosla
-
Crystal Lake, Illinois, Vereinigte Staaten, 60014
- Rekrutierung
- AMG Crystal Lake - Oncology
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-929-6129
- E-Mail: advocateresearch@advocate.com
-
Hauptermittler:
- Antony Ruggeri
-
Danville, Illinois, Vereinigte Staaten, 61832
- Rekrutierung
- Carle at The Riverfront
-
Hauptermittler:
- Tanmay Sahai
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@Carle.com
-
DeKalb, Illinois, Vereinigte Staaten, 60115
- Rekrutierung
- Northwestern Medicine Cancer Center Kishwaukee
-
Hauptermittler:
- Devalingam Mahalingam
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-352-5360
- E-Mail: Donald.Smith3@nm.org
-
Decatur, Illinois, Vereinigte Staaten, 62526
- Rekrutierung
- Cancer Care Specialists of Illinois - Decatur
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-Mail: morganthaler.jodi@mhsil.com
-
Decatur, Illinois, Vereinigte Staaten, 62526
- Rekrutierung
- Decatur Memorial Hospital
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-Mail: morganthaler.jodi@mhsil.com
-
Dixon, Illinois, Vereinigte Staaten, 61021
- Rekrutierung
- Illinois CancerCare-Dixon
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 815-285-7800
-
Downers Grove, Illinois, Vereinigte Staaten, 60515
- Rekrutierung
- Advocate Good Samaritan Hospital
-
Hauptermittler:
- Antony Ruggeri
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-275-1270
- E-Mail: Barbara.barhamand@advocatehealth.com
-
Effingham, Illinois, Vereinigte Staaten, 62401
- Rekrutierung
- Carle Physician Group-Effingham
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@carle.com
-
Hauptermittler:
- Tanmay Sahai
-
Effingham, Illinois, Vereinigte Staaten, 62401
- Rekrutierung
- Crossroads Cancer Center
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-Mail: morganthaler.jodi@mhsil.com
-
Elgin, Illinois, Vereinigte Staaten, 60123
- Rekrutierung
- Advocate Sherman Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-429-2907
-
Hauptermittler:
- Antony Ruggeri
-
Eureka, Illinois, Vereinigte Staaten, 61530
- Rekrutierung
- Illinois CancerCare-Eureka
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Evanston, Illinois, Vereinigte Staaten, 60201
- Rekrutierung
- NorthShore University HealthSystem-Evanston Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-570-2109
-
Hauptermittler:
- Mary T. Jenkins Vogel
-
Galesburg, Illinois, Vereinigte Staaten, 61401
- Rekrutierung
- Illinois CancerCare-Galesburg
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Geneva, Illinois, Vereinigte Staaten, 60134
- Rekrutierung
- Northwestern Medicine Cancer Center Delnor
-
Hauptermittler:
- Devalingam Mahalingam
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-352-5360
- E-Mail: Donald.Smith3@nm.org
-
Glenview, Illinois, Vereinigte Staaten, 60026
- Rekrutierung
- NorthShore University HealthSystem-Glenbrook Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-570-2109
-
Hauptermittler:
- Mary T. Jenkins Vogel
-
Glenview, Illinois, Vereinigte Staaten, 60026
- Rekrutierung
- Northwestern Medicine Glenview Outpatient Center
-
Hauptermittler:
- Devalingam Mahalingam
-
Kontakt:
- Site Public Contact
- Telefonnummer: 312-695-1102
-
Grayslake, Illinois, Vereinigte Staaten, 60030
- Rekrutierung
- Northwestern Medicine Grayslake Outpatient Center
-
Hauptermittler:
- Devalingam Mahalingam
-
Kontakt:
- Site Public Contact
- Telefonnummer: 312-695-1102
-
Harvey, Illinois, Vereinigte Staaten, 60426
- Rekrutierung
- Ingalls Memorial Hospital
-
Hauptermittler:
- James A. Wallace
-
Kontakt:
- Site Public Contact
- Telefonnummer: 708-915-4673
- E-Mail: clinicaltrials@ingalls.org
-
Hazel Crest, Illinois, Vereinigte Staaten, 60429
- Rekrutierung
- Advocate South Suburban Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 708-799-9995
-
Hauptermittler:
- Antony Ruggeri
-
Highland Park, Illinois, Vereinigte Staaten, 60035
- Rekrutierung
- NorthShore University HealthSystem-Highland Park Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-570-2109
-
Hauptermittler:
- Mary T. Jenkins Vogel
-
Kewanee, Illinois, Vereinigte Staaten, 61443
- Rekrutierung
- Illinois CancerCare-Kewanee Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Lake Forest, Illinois, Vereinigte Staaten, 60045
- Rekrutierung
- Northwestern Medicine Lake Forest Hospital
-
Hauptermittler:
- Devalingam Mahalingam
-
Kontakt:
- Site Public Contact
- E-Mail: cancertrials@northwestern.edu
-
Libertyville, Illinois, Vereinigte Staaten, 60048
- Rekrutierung
- AMG Libertyville - Oncology
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-929-6129
- E-Mail: advocateresearch@advocatehealth.com
-
Hauptermittler:
- Antony Ruggeri
-
Libertyville, Illinois, Vereinigte Staaten, 60048
- Rekrutierung
- Condell Memorial Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-929-6129
- E-Mail: advocateresearch@advocatehealth.com
-
Hauptermittler:
- Antony Ruggeri
-
Macomb, Illinois, Vereinigte Staaten, 61455
- Rekrutierung
- Illinois CancerCare-Macomb
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Mattoon, Illinois, Vereinigte Staaten, 61938
- Rekrutierung
- Carle Physician Group-Mattoon/Charleston
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@carle.com
-
Hauptermittler:
- Tanmay Sahai
-
Maywood, Illinois, Vereinigte Staaten, 60153
- Rekrutierung
- Loyola University Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 708-226-4357
-
Hauptermittler:
- Nan Sethakorn
-
Mount Vernon, Illinois, Vereinigte Staaten, 62864
- Rekrutierung
- SSM Health Good Samaritan
-
Hauptermittler:
- Jay W. Carlson
-
Kontakt:
- Site Public Contact
- Telefonnummer: 618-899-1894
- E-Mail: gayla.hall@ssmhealth.com
-
New Lenox, Illinois, Vereinigte Staaten, 60451
- Rekrutierung
- UC Comprehensive Cancer Center at Silver Cross
-
Kontakt:
- Site Public Contact
- Telefonnummer: 773-702-8222
- E-Mail: cancerclinicaltrials@bsd.uchicago.edu
-
Hauptermittler:
- Ardaman Shergill
-
Normal, Illinois, Vereinigte Staaten, 61761
- Rekrutierung
- Carle BroMenn Medical Center
-
Hauptermittler:
- Tanmay Sahai
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@Carle.com
-
Normal, Illinois, Vereinigte Staaten, 61761
- Rekrutierung
- Carle Cancer Institute Normal
-
Hauptermittler:
- Tanmay Sahai
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@Carle.com
-
O'Fallon, Illinois, Vereinigte Staaten, 62269
- Rekrutierung
- Cancer Care Center of O'Fallon
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-Mail: morganthaler.jodi@mhsil.com
-
Oak Lawn, Illinois, Vereinigte Staaten, 60453-2699
- Rekrutierung
- Advocate Christ Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-323-8622
-
Hauptermittler:
- Antony Ruggeri
-
Orland Park, Illinois, Vereinigte Staaten, 60462
- Rekrutierung
- University of Chicago Medicine-Orland Park
-
Kontakt:
- Site Public Contact
- Telefonnummer: 773-702-8222
- E-Mail: cancerclinicaltrials@bsd.uchicago.edu
-
Hauptermittler:
- Ardaman Shergill
-
Orland Park, Illinois, Vereinigte Staaten, 60462
- Rekrutierung
- Northwestern Medicine Orland Park
-
Hauptermittler:
- Devalingam Mahalingam
-
Kontakt:
- Site Public Contact
- E-Mail: nctnprogram_rhlccc@northwestern.edu
-
Ottawa, Illinois, Vereinigte Staaten, 61350
- Rekrutierung
- Illinois CancerCare-Ottawa Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Park Ridge, Illinois, Vereinigte Staaten, 60068
- Rekrutierung
- Advocate Lutheran General Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-384-3621
-
Hauptermittler:
- Antony Ruggeri
-
Pekin, Illinois, Vereinigte Staaten, 61554
- Rekrutierung
- Illinois CancerCare-Pekin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Peoria, Illinois, Vereinigte Staaten, 61615
- Rekrutierung
- Illinois CancerCare-Peoria
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Peru, Illinois, Vereinigte Staaten, 61354
- Rekrutierung
- Illinois CancerCare-Peru
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Princeton, Illinois, Vereinigte Staaten, 61356
- Rekrutierung
- Illinois CancerCare-Princeton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Rockford, Illinois, Vereinigte Staaten, 61114
- Rekrutierung
- Mercyhealth Cancer Institute - Rockford
-
Hauptermittler:
- Mayur Narkhede
-
Kontakt:
- Site Public Contact
- Telefonnummer: 815-971-5858
- E-Mail: oncologyclinicaltrials@mhemail.org
-
Shiloh, Illinois, Vereinigte Staaten, 62269
- Rekrutierung
- Memorial Hospital East
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-747-9912
- E-Mail: dschwab@wustl.edu
-
Hauptermittler:
- Nusayba Bagegni
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Rekrutierung
- Southern Illinois University School of Medicine
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-545-7929
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Rekrutierung
- Springfield Clinic
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-444-7541
-
Springfield, Illinois, Vereinigte Staaten, 62781
- Rekrutierung
- Springfield Memorial Hospital
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-528-7541
- E-Mail: pallante.beth@mhsil.com
-
Urbana, Illinois, Vereinigte Staaten, 61801
- Rekrutierung
- Carle Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@carle.com
-
Hauptermittler:
- Tanmay Sahai
-
Warrenville, Illinois, Vereinigte Staaten, 60555
- Rekrutierung
- Northwestern Medicine Cancer Center Warrenville
-
Hauptermittler:
- Devalingam Mahalingam
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-352-5360
- E-Mail: Donald.Smith3@nm.org
-
Washington, Illinois, Vereinigte Staaten, 61571
- Rekrutierung
- Illinois CancerCare - Washington
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Zion, Illinois, Vereinigte Staaten, 60099
- Aktiv, nicht rekrutierend
- Midwestern Regional Medical Center
-
-
Indiana
-
Crown Point, Indiana, Vereinigte Staaten, 46307
- Rekrutierung
- UChicago Medicine Northwest Indiana
-
Hauptermittler:
- Ardaman Shergill
-
Kontakt:
- Site Public Contact
- Telefonnummer: 855-702-8222
- E-Mail: cancerclinicaltrials@bsd.uchicago.edu
-
Michigan City, Indiana, Vereinigte Staaten, 46360
- Rekrutierung
- Woodland Cancer Care Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 219-861-5800
- E-Mail: Anna.Huron@franciscanalliance.org
-
Hauptermittler:
- William H. Bae
-
Richmond, Indiana, Vereinigte Staaten, 47374
- Suspendiert
- Reid Health
-
South Bend, Indiana, Vereinigte Staaten, 46601
- Aktiv, nicht rekrutierend
- Memorial Hospital of South Bend
-
-
Iowa
-
Ankeny, Iowa, Vereinigte Staaten, 50023
- Rekrutierung
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-3305
-
Hauptermittler:
- Seema Harichand-Herdt
-
Cedar Rapids, Iowa, Vereinigte Staaten, 52403
- Rekrutierung
- Mercy Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 319-365-4673
-
Hauptermittler:
- Deborah W. Wilbur
-
Cedar Rapids, Iowa, Vereinigte Staaten, 52403
- Rekrutierung
- Oncology Associates at Mercy Medical Center
-
Hauptermittler:
- Deborah W. Wilbur
-
Kontakt:
- Site Public Contact
- Telefonnummer: 319-363-2690
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- Rekrutierung
- Mercy Medical Center - Des Moines
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-3305
-
Hauptermittler:
- Richard L. Deming
-
Des Moines, Iowa, Vereinigte Staaten, 50309
- Rekrutierung
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-3305
-
Hauptermittler:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- Rekrutierung
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-3305
-
Hauptermittler:
- Seema Harichand-Herdt
-
Waukee, Iowa, Vereinigte Staaten, 50263
- Rekrutierung
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-3305
-
Hauptermittler:
- Seema Harichand-Herdt
-
-
Kentucky
-
Lexington, Kentucky, Vereinigte Staaten, 40536
- Rekrutierung
- University of Kentucky/Markey Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 859-257-3379
-
Hauptermittler:
- Susanne M. Arnold
-
Lexington, Kentucky, Vereinigte Staaten, 40509
- Rekrutierung
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
Hauptermittler:
- Loretta J. Nastoupil
-
Kontakt:
- Site Public Contact
- Telefonnummer: 720-874-1881
- E-Mail: ResearchInstituteInquiries@CommonSpirit.org
-
Paducah, Kentucky, Vereinigte Staaten, 42003
- Aktiv, nicht rekrutierend
- Mercy Health - Paducah Cancer Center
-
-
Louisiana
-
Metairie, Louisiana, Vereinigte Staaten, 70006
- Aktiv, nicht rekrutierend
- East Jefferson General Hospital
-
New Orleans, Louisiana, Vereinigte Staaten, 70121
- Rekrutierung
- Ochsner Medical Center Jefferson
-
Hauptermittler:
- John T. Cole
-
Kontakt:
- Site Public Contact
- Telefonnummer: 504-842-8084
- E-Mail: Elisemarie.curry@ochsner.org
-
New Orleans, Louisiana, Vereinigte Staaten, 70112
- Aktiv, nicht rekrutierend
- University Medical Center New Orleans
-
-
Maine
-
Augusta, Maine, Vereinigte Staaten, 04330
- Rekrutierung
- Harold Alfond Center for Cancer Care
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-626-4855
-
Hauptermittler:
- Leslie S. Bradford
-
Brewer, Maine, Vereinigte Staaten, 04412
- Rekrutierung
- Lafayette Family Cancer Center-EMMC
-
Hauptermittler:
- Sarah J. Sinclair
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-987-3005
-
Scarborough, Maine, Vereinigte Staaten, 04074
- Rekrutierung
- MaineHealth Maine Medical Center- Scarborough
-
Hauptermittler:
- Leslie S. Bradford
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-396-8670
- E-Mail: clinicalresearch@mainehealth.org
-
South Portland, Maine, Vereinigte Staaten, 04106
- Rekrutierung
- MaineHealth Cancer Care and IV Therapy - South Portland
-
Hauptermittler:
- Leslie S. Bradford
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-396-8670
- E-Mail: clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21201
- Rekrutierung
- University of Maryland/Greenebaum Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-888-8823
-
Hauptermittler:
- Ranee Mehra
-
Bethesda, Maryland, Vereinigte Staaten, 20892
- Rekrutierung
- National Institutes of Health Clinical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-411-1222
-
Hauptermittler:
- A P. Chen
-
Bethesda, Maryland, Vereinigte Staaten, 20889-5600
- Rekrutierung
- Walter Reed National Military Medical Center
-
Hauptermittler:
- Jeremy G. Perkins
-
Kontakt:
- Site Public Contact
- Telefonnummer: 301-319-2100
-
Cumberland, Maryland, Vereinigte Staaten, 21502
- Rekrutierung
- UPMC Western Maryland
-
Kontakt:
- Site Public Contact
- Telefonnummer: 240-964-1400
-
Hauptermittler:
- Adam M. Brufsky
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Rekrutierung
- Dana-Farber Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-442-3324
-
Hauptermittler:
- Geoffrey I. Shapiro
-
Boston, Massachusetts, Vereinigte Staaten, 02111
- Rekrutierung
- Tufts Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 617-636-5000
- E-Mail: ContactUsCancerCenter@TuftsMedicalCenter.org
-
Hauptermittler:
- Francis W. Nugent
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Aktiv, nicht rekrutierend
- Beth Israel Deaconess Medical Center
-
Springfield, Massachusetts, Vereinigte Staaten, 01199
- Rekrutierung
- Baystate Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 413-794-3565
- E-Mail: tamara.wrenn@baystatehealth.org
-
Hauptermittler:
- Tashanna K. Myers
-
Stoneham, Massachusetts, Vereinigte Staaten, 02180
- Rekrutierung
- Tufts Medical Center Cancer Center Stoneham
-
Hauptermittler:
- Francis W. Nugent
-
Kontakt:
- Site Public Contact
- Telefonnummer: 617-636-3264
- E-Mail: NCCCR@Tuftsmedicalcenter.org
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- Rekrutierung
- University of Michigan Rogel Cancer Center
-
Hauptermittler:
- Anne F. Schott
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-865-1125
- E-Mail: CancerAnswerLine@med.umich.edu
-
Ann Arbor, Michigan, Vereinigte Staaten, 48106
- Rekrutierung
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Battle Creek, Michigan, Vereinigte Staaten, 49017
- Rekrutierung
- Bronson Battle Creek
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-Mail: crcwm-regulatory@crcwm.org
-
Hauptermittler:
- Kathleen Y. Butler
-
Brighton, Michigan, Vereinigte Staaten, 48114
- Rekrutierung
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Brighton, Michigan, Vereinigte Staaten, 48116
- Rekrutierung
- University of Michigan - Brighton Center for Specialty Care
-
Hauptermittler:
- Anne F. Schott
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-865-1125
-
Brighton, Michigan, Vereinigte Staaten, 48114
- Rekrutierung
- Trinity Health Medical Center - Brighton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Canton, Michigan, Vereinigte Staaten, 48188
- Rekrutierung
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Canton, Michigan, Vereinigte Staaten, 48188
- Rekrutierung
- Trinity Health Medical Center - Canton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Chelsea, Michigan, Vereinigte Staaten, 48118
- Rekrutierung
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Chelsea, Michigan, Vereinigte Staaten, 48118
- Rekrutierung
- Chelsea Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Dearborn, Michigan, Vereinigte Staaten, 48124
- Rekrutierung
- Corewell Health Dearborn Hospital
-
Hauptermittler:
- Dana Zakalik
-
Kontakt:
- Site Public Contact
- Telefonnummer: 248-551-7695
-
Escanaba, Michigan, Vereinigte Staaten, 49829
- Rekrutierung
- OSF Saint Francis Hospital and Medical Group
-
Hauptermittler:
- Brian L. Burnette
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-433-8889
- E-Mail: WI_research_admin@hshs.org
-
Farmington Hills, Michigan, Vereinigte Staaten, 48336
- Suspendiert
- Corewell Health Farmington Hills Hospital
-
Flint, Michigan, Vereinigte Staaten, 48503
- Rekrutierung
- Genesys Hurley Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 810-762-8038
- E-Mail: wstrong@ghci.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Flint, Michigan, Vereinigte Staaten, 48503
- Rekrutierung
- Hurley Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 810-762-8038
- E-Mail: wstrong@ghci.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Flint, Michigan, Vereinigte Staaten, 48503
- Suspendiert
- Genesee Hematology Oncology PC
-
Flint, Michigan, Vereinigte Staaten, 48503
- Rekrutierung
- Cancer Hematology Centers - Flint
-
Kontakt:
- Site Public Contact
- Telefonnummer: 810-762-8038
- E-Mail: wstrong@ghci.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Grand Rapids, Michigan, Vereinigte Staaten, 49503
- Rekrutierung
- Trinity Health Grand Rapids Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-Mail: crcwm-regulatory@crcwm.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Grand Rapids, Michigan, Vereinigte Staaten, 49503
- Rekrutierung
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-Mail: crcwm-regulatory@crcwm.org
-
Hauptermittler:
- Kathleen Y. Butler
-
Kalamazoo, Michigan, Vereinigte Staaten, 49007
- Rekrutierung
- Bronson Methodist Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-Mail: crcwm-regulatory@crcwm.org
-
Hauptermittler:
- Kathleen Y. Butler
-
Kalamazoo, Michigan, Vereinigte Staaten, 49007
- Rekrutierung
- West Michigan Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-Mail: crcwm-regulatory@crcwm.org
-
Hauptermittler:
- Kathleen Y. Butler
-
Kalamazoo, Michigan, Vereinigte Staaten, 49009
- Rekrutierung
- Beacon Kalamazoo Cancer Center
-
Hauptermittler:
- Kathleen Y. Butler
-
Kontakt:
- Site Public Contact
- Telefonnummer: 574-647-7370
-
Kalamazoo, Michigan, Vereinigte Staaten, 49048
- Rekrutierung
- Beacon Kalamazoo
-
Hauptermittler:
- Kathleen Y. Butler
-
Kontakt:
- Site Public Contact
- Telefonnummer: 574-647-7370
-
Lansing, Michigan, Vereinigte Staaten, 48912
- Rekrutierung
- University of Michigan Health - Sparrow Lansing
-
Hauptermittler:
- Tareq Al baghdadi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 517-364-3712
- E-Mail: harsha.trivedi@umhsparrow.org
-
Livonia, Michigan, Vereinigte Staaten, 48154
- Rekrutierung
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Macomb, Michigan, Vereinigte Staaten, 48044
- Rekrutierung
- Henry Ford Saint John Hospital - Macomb Medical
-
Hauptermittler:
- Tareq Al baghdadi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-343-3166
- E-Mail: kforman1@hfhs.org
-
Manistique, Michigan, Vereinigte Staaten, 49854
- Rekrutierung
- Schoolcraft Memorial Hospital
-
Hauptermittler:
- Brian L. Burnette
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-433-8889
- E-Mail: WI_research_admin@hshs.org
-
Muskegon, Michigan, Vereinigte Staaten, 49444
- Rekrutierung
- Trinity Health Muskegon Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-Mail: crcwm-regulatory@crcwm.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Niles, Michigan, Vereinigte Staaten, 49120
- Rekrutierung
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
-
Hauptermittler:
- Kathleen Y. Butler
-
Norton Shores, Michigan, Vereinigte Staaten, 49444
- Rekrutierung
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-Mail: connie.szczepanek@crcwm.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Pontiac, Michigan, Vereinigte Staaten, 48341
- Rekrutierung
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Pontiac, Michigan, Vereinigte Staaten, 48341
- Rekrutierung
- Michigan Healthcare Professionals Pontiac
-
Hauptermittler:
- Tareq Al baghdadi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 248-858-6215
- E-Mail: Emily.Crofts@trinity-health.org
-
Reed City, Michigan, Vereinigte Staaten, 49677
- Rekrutierung
- Corewell Health Reed City Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-Mail: crcwm-regulatory@crcwm.org
-
Hauptermittler:
- Kathleen Y. Butler
-
Royal Oak, Michigan, Vereinigte Staaten, 48073
- Rekrutierung
- Corewell Health William Beaumont University Hospital
-
Hauptermittler:
- Dana Zakalik
-
Kontakt:
- Site Public Contact
- Telefonnummer: 248-551-7695
-
Royal Oak, Michigan, Vereinigte Staaten, 48073
- Rekrutierung
- Corewell Health Children's
-
Hauptermittler:
- Dana Zakalik
-
Kontakt:
- Site Public Contact
- Telefonnummer: 248-551-7695
-
Saginaw, Michigan, Vereinigte Staaten, 48604
- Suspendiert
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Vereinigte Staaten, 48601
- Rekrutierung
- MyMichigan Medical Center Saginaw
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Saint Joseph, Michigan, Vereinigte Staaten, 49085
- Rekrutierung
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-Mail: crcwm-regulatory@crcwm.org
-
Hauptermittler:
- Kathleen Y. Butler
-
Saint Joseph, Michigan, Vereinigte Staaten, 49085
- Rekrutierung
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-Mail: crcwm-regulatory@crcwm.org
-
Hauptermittler:
- Kathleen Y. Butler
-
Tawas City, Michigan, Vereinigte Staaten, 48764
- Rekrutierung
- MyMichigan Medical Center Tawas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Traverse City, Michigan, Vereinigte Staaten, 49684
- Rekrutierung
- Munson Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-Mail: crcwm-regulatory@crcwm.org
-
Hauptermittler:
- Kathleen Y. Butler
-
Troy, Michigan, Vereinigte Staaten, 48085
- Rekrutierung
- Corewell Health Beaumont Troy Hospital
-
Hauptermittler:
- Dana Zakalik
-
Kontakt:
- Site Public Contact
- Telefonnummer: 248-551-7695
-
West Branch, Michigan, Vereinigte Staaten, 48661
- Suspendiert
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Wyoming, Michigan, Vereinigte Staaten, 49519
- Rekrutierung
- University of Michigan Health - West
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-Mail: crcwm-regulatory@crcwm.org
-
Hauptermittler:
- Kathleen Y. Butler
-
Ypsilanti, Michigan, Vereinigte Staaten, 48106
- Rekrutierung
- Huron Gastroenterology PC
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Ypsilanti, Michigan, Vereinigte Staaten, 48197
- Rekrutierung
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Tareq Al baghdadi
-
-
Minnesota
-
Bemidji, Minnesota, Vereinigte Staaten, 56601
- Rekrutierung
- Sanford Joe Lueken Cancer Center
-
Hauptermittler:
- Daniel Almquist
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-333-5000
- E-Mail: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Coon Rapids, Minnesota, Vereinigte Staaten, 55433
- Rekrutierung
- Mercy Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Deer River, Minnesota, Vereinigte Staaten, 56636
- Rekrutierung
- Essentia Health - Deer River Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-Mail: CancerTrials@EssentiaHealth.org
-
Hauptermittler:
- Bret E. Friday
-
Duluth, Minnesota, Vereinigte Staaten, 55805
- Rekrutierung
- Essentia Health Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-Mail: CancerTrials@EssentiaHealth.org
-
Hauptermittler:
- Bret E. Friday
-
Edina, Minnesota, Vereinigte Staaten, 55435
- Rekrutierung
- Fairview Southdale Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Edina, Minnesota, Vereinigte Staaten, 55435
- Rekrutierung
- Minnesota Oncology - Edina
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Hibbing, Minnesota, Vereinigte Staaten, 55746
- Rekrutierung
- Essentia Health Hibbing Clinic
-
Hauptermittler:
- Bret E. Friday
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
-
Maple Grove, Minnesota, Vereinigte Staaten, 55369
- Rekrutierung
- Fairview Clinics and Surgery Center Maple Grove
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Maplewood, Minnesota, Vereinigte Staaten, 55109
- Rekrutierung
- Saint John's Hospital - Healtheast
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Minneapolis, Minnesota, Vereinigte Staaten, 55407
- Rekrutierung
- Abbott-Northwestern Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Rekrutierung
- Mayo Clinic in Rochester
-
Kontakt:
- Site Public Contact
- Telefonnummer: 855-776-0015
-
Hauptermittler:
- Aaron S. Mansfield
-
Saint Louis Park, Minnesota, Vereinigte Staaten, 55416
- Rekrutierung
- Park Nicollet Clinic - Saint Louis Park
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Saint Paul, Minnesota, Vereinigte Staaten, 55101
- Rekrutierung
- Regions Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Saint Paul, Minnesota, Vereinigte Staaten, 55102
- Rekrutierung
- United Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Sandstone, Minnesota, Vereinigte Staaten, 55072
- Rekrutierung
- Essentia Health Sandstone
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-Mail: CancerTrials@EssentiaHealth.org
-
Hauptermittler:
- Bret E. Friday
-
Virginia, Minnesota, Vereinigte Staaten, 55792
- Rekrutierung
- Essentia Health Virginia Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-Mail: CancerTrials@EssentiaHealth.org
-
Hauptermittler:
- Bret E. Friday
-
-
Mississippi
-
Columbus, Mississippi, Vereinigte Staaten, 39705
- Rekrutierung
- Baptist Memorial Hospital and Cancer Center-Golden Triangle
-
Kontakt:
- Site Public Contact
- Telefonnummer: 901-226-1366
- E-Mail: BCCclintrials@bmhcc.org
-
Hauptermittler:
- Andrew J. Benefield
-
Grenada, Mississippi, Vereinigte Staaten, 38901
- Rekrutierung
- Baptist Cancer Center-Grenada
-
Kontakt:
- Site Public Contact
- Telefonnummer: 901-226-1366
- E-Mail: BCCclintrials@bmhcc.org
-
Hauptermittler:
- Andrew J. Benefield
-
Gulfport, Mississippi, Vereinigte Staaten, 39502
- Aktiv, nicht rekrutierend
- Gulfport Memorial Hospital
-
New Albany, Mississippi, Vereinigte Staaten, 38652
- Rekrutierung
- Baptist Memorial Hospital and Cancer Center-Union County
-
Kontakt:
- Site Public Contact
- Telefonnummer: 901-226-1366
- E-Mail: BCCclintrials@bmhcc.org
-
Hauptermittler:
- Andrew J. Benefield
-
Oxford, Mississippi, Vereinigte Staaten, 38655
- Rekrutierung
- Baptist Memorial Hospital and Cancer Center-Oxford
-
Kontakt:
- Site Public Contact
- Telefonnummer: 901-226-1366
- E-Mail: BCCclintrials@bmhcc.org
-
Hauptermittler:
- Andrew J. Benefield
-
Southhaven, Mississippi, Vereinigte Staaten, 38671
- Rekrutierung
- Baptist Memorial Hospital and Cancer Center-Desoto
-
Kontakt:
- Site Public Contact
- Telefonnummer: 901-226-1366
- E-Mail: BCCclintrials@bmhcc.org
-
Hauptermittler:
- Andrew J. Benefield
-
-
Missouri
-
Cape Girardeau, Missouri, Vereinigte Staaten, 63703
- Rekrutierung
- Saint Francis Medical Center
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 573-334-2230
- E-Mail: sfmc@sfmc.net
-
Chesterfield, Missouri, Vereinigte Staaten, 63017
- Rekrutierung
- Saint Luke's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-205-6936
-
Hauptermittler:
- Meera Rana
-
City of Saint Peters, Missouri, Vereinigte Staaten, 63376
- Rekrutierung
- Siteman Cancer Center at Saint Peters Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-Mail: info@siteman.wustl.edu
-
Hauptermittler:
- Nusayba Bagegni
-
Creve Coeur, Missouri, Vereinigte Staaten, 63141
- Rekrutierung
- Siteman Cancer Center at West County Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-Mail: info@siteman.wustl.edu
-
Hauptermittler:
- Nusayba Bagegni
-
Farmington, Missouri, Vereinigte Staaten, 63640
- Rekrutierung
- Parkland Health Center - Farmington
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
Rolla, Missouri, Vereinigte Staaten, 65401
- Suspendiert
- Phelps Health Delbert Day Cancer Institute
-
Saint Joseph, Missouri, Vereinigte Staaten, 64506
- Rekrutierung
- Heartland Regional Medical Center
-
Hauptermittler:
- Jay W. Carlson
-
Kontakt:
- Site Public Contact
- Telefonnummer: 816-271-7937
- E-Mail: Trisha.England2@mymlc.com
-
Sainte Genevieve, Missouri, Vereinigte Staaten, 63670
- Rekrutierung
- Sainte Genevieve County Memorial Hospital
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
Springfield, Missouri, Vereinigte Staaten, 65804
- Rekrutierung
- Mercy Hospital Springfield
-
Hauptermittler:
- Jay W. Carlson
-
Kontakt:
- Site Public Contact
- Telefonnummer: 417-269-4520
-
Springfield, Missouri, Vereinigte Staaten, 65807
- Rekrutierung
- CoxHealth South Hospital
-
Hauptermittler:
- Jay W. Carlson
-
Kontakt:
- Site Public Contact
- Telefonnummer: 417-269-4520
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Rekrutierung
- Washington University School of Medicine
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-Mail: info@siteman.wustl.edu
-
Hauptermittler:
- Nusayba Bagegni
-
St Louis, Missouri, Vereinigte Staaten, 63128
- Rekrutierung
- Mercy Hospital South
-
Hauptermittler:
- Jay W. Carlson
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-525-6042
- E-Mail: Danielle.Werle@mercy.net
-
St Louis, Missouri, Vereinigte Staaten, 63141
- Rekrutierung
- Mercy Hospital Saint Louis
-
Hauptermittler:
- Jay W. Carlson
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-251-7066
-
St Louis, Missouri, Vereinigte Staaten, 63129
- Rekrutierung
- Siteman Cancer Center-South County
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-Mail: info@siteman.wustl.edu
-
Hauptermittler:
- Nusayba Bagegni
-
St Louis, Missouri, Vereinigte Staaten, 63136
- Rekrutierung
- Siteman Cancer Center at Christian Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-Mail: info@siteman.wustl.edu
-
Hauptermittler:
- Nusayba Bagegni
-
St Louis, Missouri, Vereinigte Staaten, 63131
- Rekrutierung
- Missouri Baptist Medical Center
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
Sullivan, Missouri, Vereinigte Staaten, 63080
- Rekrutierung
- Missouri Baptist Sullivan Hospital
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
-
Montana
-
Anaconda, Montana, Vereinigte Staaten, 59711
- Rekrutierung
- Community Hospital of Anaconda
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Billings, Montana, Vereinigte Staaten, 59101
- Rekrutierung
- Billings Clinic Cancer Center
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-996-2663
- E-Mail: research@billingsclinic.org
-
Bozeman, Montana, Vereinigte Staaten, 59715
- Rekrutierung
- Bozeman Health Deaconess Hospital
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Great Falls, Montana, Vereinigte Staaten, 59405
- Rekrutierung
- Benefis Sletten Cancer Institute
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Kalispell, Montana, Vereinigte Staaten, 59901
- Rekrutierung
- Logan Health Medical Center
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Missoula, Montana, Vereinigte Staaten, 59804
- Rekrutierung
- Community Medical Center
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
-
Nebraska
-
Bellevue, Nebraska, Vereinigte Staaten, 68123
- Aktiv, nicht rekrutierend
- Nebraska Medicine-Bellevue
-
Omaha, Nebraska, Vereinigte Staaten, 68198
- Aktiv, nicht rekrutierend
- University of Nebraska Medical Center
-
Omaha, Nebraska, Vereinigte Staaten, 68118
- Aktiv, nicht rekrutierend
- Nebraska Medicine-Village Pointe
-
-
Nevada
-
Las Vegas, Nevada, Vereinigte Staaten, 89102
- Rekrutierung
- OptumCare Cancer Care at Charleston
-
Kontakt:
- Site Public Contact
- Telefonnummer: 702-384-0013
- E-Mail: research@sncrf.org
-
Hauptermittler:
- Khawaja S. Jahangir
-
Las Vegas, Nevada, Vereinigte Staaten, 89135
- Rekrutierung
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Kontakt:
- Site Public Contact
- Telefonnummer: 702-384-0013
- E-Mail: research@sncrf.org
-
Hauptermittler:
- Khawaja S. Jahangir
-
Las Vegas, Nevada, Vereinigte Staaten, 89144
- Rekrutierung
- Summerlin Hospital Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 702-384-0013
- E-Mail: research@sncrf.org
-
Hauptermittler:
- Khawaja S. Jahangir
-
Las Vegas, Nevada, Vereinigte Staaten, 89183
- Suspendiert
- OptumCare Cancer Care at Fort Apache
-
Reno, Nevada, Vereinigte Staaten, 89502
- Rekrutierung
- Renown Regional Medical Center
-
Hauptermittler:
- Khawaja S. Jahangir
-
Kontakt:
- Site Public Contact
- Telefonnummer: 775-982-5050
- E-Mail: Renown-CRD@renown.org
-
-
New Jersey
-
Flemington, New Jersey, Vereinigte Staaten, 08822
- Rekrutierung
- Hunterdon Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 908-237-2330
-
Hauptermittler:
- Myron E. Bednar
-
Lakewood, New Jersey, Vereinigte Staaten, 08701
- Rekrutierung
- Monmouth Medical Center Southern Campus
-
Hauptermittler:
- Patrick M. Boland
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-923-6564
- E-Mail: mary.danish@rwjbh.org
-
Livingston, New Jersey, Vereinigte Staaten, 07039
- Rekrutierung
- Cooperman Barnabas Medical Center
-
Hauptermittler:
- Patrick M. Boland
-
Kontakt:
- Site Public Contact
- Telefonnummer: 973-322-5200
-
Long Branch, New Jersey, Vereinigte Staaten, 07740
- Rekrutierung
- Monmouth Medical Center
-
Hauptermittler:
- Patrick M. Boland
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-923-6564
- E-Mail: mary.danish@rwjbh.org
-
Middletown, New Jersey, Vereinigte Staaten, 07748
- Rekrutierung
- Memorial Sloan Kettering Monmouth
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-639-7592
-
Hauptermittler:
- Alison M. Schram
-
New Brunswick, New Jersey, Vereinigte Staaten, 08903
- Rekrutierung
- Rutgers Cancer Institute of New Jersey
-
Hauptermittler:
- Patrick M. Boland
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-235-7356
-
Pennington, New Jersey, Vereinigte Staaten, 08534
- Suspendiert
- Capital Health Medical Center-Hopewell
-
Sewell, New Jersey, Vereinigte Staaten, 08080
- Rekrutierung
- Sidney Kimmel Cancer Center Washington Township
-
Kontakt:
- Site Public Contact
- Telefonnummer: 215-600-9151
- E-Mail: ONCTrialNow@jefferson.edu
-
Hauptermittler:
- Jennifer M. Johnson
-
Somerville, New Jersey, Vereinigte Staaten, 08876
- Rekrutierung
- Robert Wood Johnson University Hospital Somerset
-
Hauptermittler:
- Patrick M. Boland
-
Kontakt:
- Site Public Contact
- Telefonnummer: 908-685-2481
- E-Mail: Siby.Varughese@rwjbh.org
-
Toms River, New Jersey, Vereinigte Staaten, 08755
- Rekrutierung
- Community Medical Center
-
Hauptermittler:
- Patrick M. Boland
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-557-8294
- E-Mail: Lennette.Gonzales@rwjbh.org
-
-
New Mexico
-
Albuquerque, New Mexico, Vereinigte Staaten, 87106
- Rekrutierung
- University of New Mexico Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 505-925-0348
- E-Mail: HSC-ClinicalTrialInfo@salud.unm.edu
-
Hauptermittler:
- Bernard Tawfik
-
-
New York
-
Buffalo, New York, Vereinigte Staaten, 14263
- Rekrutierung
- Roswell Park Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-767-9355
- E-Mail: askroswell@roswellpark.org
-
Hauptermittler:
- Ellis G. Levine
-
Commack, New York, Vereinigte Staaten, 11725
- Rekrutierung
- Memorial Sloan Kettering Commack
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-639-7592
-
Hauptermittler:
- Alison M. Schram
-
Harrison, New York, Vereinigte Staaten, 10604
- Rekrutierung
- Memorial Sloan Kettering Westchester
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-639-7592
-
Hauptermittler:
- Alison M. Schram
-
Mineola, New York, Vereinigte Staaten, 11501
- Rekrutierung
- NYU Langone Hospital - Long Island
-
Hauptermittler:
- Kristen R. Spencer
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-263-4432
- E-Mail: cancertrials@nyulangone.org
-
New York, New York, Vereinigte Staaten, 10065
- Rekrutierung
- Memorial Sloan Kettering Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-639-7592
-
Hauptermittler:
- Alison M. Schram
-
New York, New York, Vereinigte Staaten, 10016
- Rekrutierung
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Hauptermittler:
- Kristen R. Spencer
-
Kontakt:
- Site Public Contact
- E-Mail: CancerTrials@nyulangone.org
-
New York, New York, Vereinigte Staaten, 10029
- Rekrutierung
- Mount Sinai Hospital
-
Hauptermittler:
- Deborah B. Doroshow
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-824-7309
- E-Mail: CCTO@mssm.edu
-
Rochester, New York, Vereinigte Staaten, 14623
- Aktiv, nicht rekrutierend
- Pluta Cancer Center
-
Syracuse, New York, Vereinigte Staaten, 13210
- Rekrutierung
- State University of New York Upstate Medical University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 315-464-5476
-
Hauptermittler:
- Mary J. Cunningham
-
The Bronx, New York, Vereinigte Staaten, 10461
- Rekrutierung
- Montefiore Medical Center-Einstein Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 718-379-6866
- E-Mail: eskwak@montefiore.org
-
Hauptermittler:
- Balazs Halmos
-
The Bronx, New York, Vereinigte Staaten, 10467
- Rekrutierung
- Montefiore Medical Center - Moses Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 718-379-6866
- E-Mail: eskwak@montefiore.org
-
Hauptermittler:
- Balazs Halmos
-
The Bronx, New York, Vereinigte Staaten, 10461
- Rekrutierung
- Montefiore Medical Center-Weiler Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 718-379-6866
- E-Mail: eskwak@montefiore.org
-
Hauptermittler:
- Balazs Halmos
-
-
North Carolina
-
Asheboro, North Carolina, Vereinigte Staaten, 27205
- Rekrutierung
- Cone Health MedCenter Asheboro
-
Kontakt:
- Site Public Contact
- Telefonnummer: 336-832-0836
- E-Mail: stacey.phelps@conehealth.com
-
Hauptermittler:
- Vinay K. Gudena
-
Burlington, North Carolina, Vereinigte Staaten, 27215
- Rekrutierung
- Cone Health Cancer Center at Alamance Regional
-
Kontakt:
- Site Public Contact
- Telefonnummer: 336-832-0836
- E-Mail: stacey.phelps@conehealth.com
-
Hauptermittler:
- Vinay K. Gudena
-
Clinton, North Carolina, Vereinigte Staaten, 28328
- Rekrutierung
- Southeastern Medical Oncology Center-Clinton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 919-587-9084
- E-Mail: jfields@cancersmoc.com
-
Hauptermittler:
- Samer S. Kasbari
-
Durham, North Carolina, Vereinigte Staaten, 27710
- Rekrutierung
- Duke University Medical Center
-
Hauptermittler:
- Angeles A. Secord
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-275-3853
-
Goldsboro, North Carolina, Vereinigte Staaten, 27534
- Rekrutierung
- Southeastern Medical Oncology Center-Goldsboro
-
Kontakt:
- Site Public Contact
- Telefonnummer: 919-587-9084
- E-Mail: jfields@cancersmoc.com
-
Hauptermittler:
- Samer S. Kasbari
-
Greensboro, North Carolina, Vereinigte Staaten, 27403
- Rekrutierung
- Cone Health Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 336-832-0836
- E-Mail: stacey.phelps@conehealth.com
-
Hauptermittler:
- Vinay K. Gudena
-
Greensboro, North Carolina, Vereinigte Staaten, 27410
- Rekrutierung
- Cone Health Cancer Center at Drawbridge Parkway
-
Kontakt:
- Site Public Contact
- Telefonnummer: 336-832-0836
- E-Mail: stacey.phelps@conehealth.com
-
Hauptermittler:
- Vinay K. Gudena
-
High Point, North Carolina, Vereinigte Staaten, 27262
- Rekrutierung
- Hayworth Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 336-802-2500
-
Hauptermittler:
- Anna Kuan-Celarier
-
Jacksonville, North Carolina, Vereinigte Staaten, 28546
- Rekrutierung
- Southeastern Medical Oncology Center-Jacksonville
-
Hauptermittler:
- Samer S. Kasbari
-
Kontakt:
- Site Public Contact
- Telefonnummer: 910-587-9084
- E-Mail: jfields@cancersmoc.com
-
Raleigh, North Carolina, Vereinigte Staaten, 27607
- Rekrutierung
- Duke Women's Cancer Care Raleigh
-
Hauptermittler:
- Angeles A. Secord
-
Kontakt:
- Site Public Contact
- Telefonnummer: 919-785-4878
-
Reidsville, North Carolina, Vereinigte Staaten, 27320
- Rekrutierung
- Annie Penn Memorial Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 336-832-0836
- E-Mail: stacey.phelps@conehealth.com
-
Hauptermittler:
- Vinay K. Gudena
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27157
- Rekrutierung
- Wake Forest University Health Sciences
-
Kontakt:
- Site Public Contact
- Telefonnummer: 336-713-6771
-
Hauptermittler:
- Anna Kuan-Celarier
-
-
North Dakota
-
Bismarck, North Dakota, Vereinigte Staaten, 58501
- Rekrutierung
- Sanford Bismarck Medical Center
-
Hauptermittler:
- Daniel Almquist
-
Kontakt:
- Site Public Contact
- Telefonnummer: 701-323-5760
- E-Mail: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Fargo, North Dakota, Vereinigte Staaten, 58122
- Rekrutierung
- Sanford Broadway Medical Center
-
Hauptermittler:
- Daniel Almquist
-
Kontakt:
- Site Public Contact
- Telefonnummer: 701-323-5760
- E-Mail: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Fargo, North Dakota, Vereinigte Staaten, 58122
- Rekrutierung
- Sanford Roger Maris Cancer Center
-
Hauptermittler:
- Daniel Almquist
-
Kontakt:
- Site Public Contact
- Telefonnummer: 701-234-6161
- E-Mail: OncologyClinicalTrialsFargo@sanfordhealth.org
-
-
Ohio
-
Athens, Ohio, Vereinigte Staaten, 45701
- Rekrutierung
- OhioHealth O'Bleness Hospital
-
Hauptermittler:
- Aine E. Clements
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-788-3860
- E-Mail: Jennifer.Sexton@ohiohealth.com
-
Avon, Ohio, Vereinigte Staaten, 44011
- Rekrutierung
- UH Seidman Cancer Center at UH Avon Health Center
-
Hauptermittler:
- Alberto J. Montero
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-641-2422
-
Beachwood, Ohio, Vereinigte Staaten, 44122
- Rekrutierung
- UHHS-Chagrin Highlands Medical Center
-
Hauptermittler:
- Alberto J. Montero
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-641-2422
- E-Mail: CTUReferral@UHhospitals.org
-
Belpre, Ohio, Vereinigte Staaten, 45714
- Rekrutierung
- Strecker Cancer Center-Belpre
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-488-2745
- E-Mail: Jeffh@columbusccop.org
-
Hauptermittler:
- Aruna C. Gowda
-
Canton, Ohio, Vereinigte Staaten, 44710
- Rekrutierung
- Aultman Health Foundation
-
Kontakt:
- Site Public Contact
- Telefonnummer: 330-363-7274
- E-Mail: ClinicalReserachDept@aultman.com
-
Hauptermittler:
- Sunitha Vemulapalli
-
Centerville, Ohio, Vereinigte Staaten, 45459
- Rekrutierung
- Miami Valley Hospital South
-
Kontakt:
- Site Public Contact
- Telefonnummer: 937-528-2900
- E-Mail: clinical.trials@daytonncorp.org
-
Hauptermittler:
- Tarek M. Sabagh
-
Chillicothe, Ohio, Vereinigte Staaten, 45601
- Rekrutierung
- Adena Regional Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-779-7585
- E-Mail: Jeffh@columbusccop.org
-
Hauptermittler:
- Aruna C. Gowda
-
Cincinnati, Ohio, Vereinigte Staaten, 45220
- Rekrutierung
- Good Samaritan Hospital - Cincinnati
-
Hauptermittler:
- Loretta J. Nastoupil
-
Kontakt:
- Site Public Contact
- Telefonnummer: 720-874-1881
- E-Mail: ResearchInstituteInquiries@CommonSpirit.org
-
Cincinnati, Ohio, Vereinigte Staaten, 45229
- Aktiv, nicht rekrutierend
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- Rekrutierung
- Case Western Reserve University
-
Hauptermittler:
- Alberto J. Montero
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-641-2422
- E-Mail: CTUReferral@UHhospitals.org
-
Cleveland, Ohio, Vereinigte Staaten, 44195
- Aktiv, nicht rekrutierend
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Vereinigte Staaten, 44111
- Aktiv, nicht rekrutierend
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus, Ohio, Vereinigte Staaten, 43213
- Rekrutierung
- Mount Carmel East Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-488-2745
- E-Mail: Jeffh@columbusccop.org
-
Hauptermittler:
- Aruna C. Gowda
-
Columbus, Ohio, Vereinigte Staaten, 43214
- Rekrutierung
- Columbus Oncology and Hematology Associates Inc
-
Hauptermittler:
- Aine E. Clements
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-788-3860
- E-Mail: Jennifer.Sexton@ohiohealth.com
-
Columbus, Ohio, Vereinigte Staaten, 43214
- Rekrutierung
- Riverside Methodist Hospital
-
Hauptermittler:
- Aine E. Clements
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-788-3860
- E-Mail: Jennifer.Sexton@ohiohealth.com
-
Columbus, Ohio, Vereinigte Staaten, 43215
- Rekrutierung
- Grant Medical Center
-
Hauptermittler:
- Aine E. Clements
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-788-3860
- E-Mail: Jennifer.Sexton@ohiohealth.com
-
Columbus, Ohio, Vereinigte Staaten, 43219
- Rekrutierung
- The Mark H Zangmeister Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-488-2745
- E-Mail: Jeffh@columbusccop.org
-
Hauptermittler:
- Aruna C. Gowda
-
Columbus, Ohio, Vereinigte Staaten, 43228
- Rekrutierung
- Doctors Hospital
-
Hauptermittler:
- Aine E. Clements
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-788-3860
- E-Mail: Jennifer.Sexton@ohiohealth.com
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Rekrutierung
- Ohio State University Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-293-5066
- E-Mail: Jamesline@osumc.edu
-
Hauptermittler:
- Floor Backes
-
Dayton, Ohio, Vereinigte Staaten, 45409
- Rekrutierung
- Miami Valley Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 937-528-2900
- E-Mail: clinical.trials@daytonncorp.org
-
Hauptermittler:
- Tarek M. Sabagh
-
Dayton, Ohio, Vereinigte Staaten, 45415
- Rekrutierung
- Miami Valley Hospital North
-
Kontakt:
- Site Public Contact
- Telefonnummer: 937-528-2900
- E-Mail: clinical.trials@daytonncorp.org
-
Hauptermittler:
- Tarek M. Sabagh
-
Dayton, Ohio, Vereinigte Staaten, 45409
- Rekrutierung
- Premier Blood and Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 937-276-8320
-
Hauptermittler:
- Tarek M. Sabagh
-
Dayton, Ohio, Vereinigte Staaten, 45415
- Suspendiert
- Dayton Physician LLC - Englewood
-
Delaware, Ohio, Vereinigte Staaten, 43015
- Rekrutierung
- Delaware Health Center-Grady Cancer Center
-
Hauptermittler:
- Aine E. Clements
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-788-3860
- E-Mail: Jennifer.Sexton@ohiohealth.com
-
Delaware, Ohio, Vereinigte Staaten, 43015
- Rekrutierung
- Grady Memorial Hospital
-
Hauptermittler:
- Aine E. Clements
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-788-3860
- E-Mail: Jennifer.Sexton@ohiohealth.com
-
Dublin, Ohio, Vereinigte Staaten, 43016
- Rekrutierung
- Columbus Oncology and Hematology Associates
-
Hauptermittler:
- Aine E. Clements
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-788-3860
- E-Mail: Jennifer.Sexton@ohiohealth.com
-
Dublin, Ohio, Vereinigte Staaten, 43016
- Rekrutierung
- Dublin Methodist Hospital
-
Hauptermittler:
- Aine E. Clements
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-788-3860
- E-Mail: Jennifer.Sexton@ohiohealth.com
-
Findlay, Ohio, Vereinigte Staaten, 45840
- Suspendiert
- Armes Family Cancer Center
-
Franklin, Ohio, Vereinigte Staaten, 45005-1066
- Rekrutierung
- Atrium Medical Center-Middletown Regional Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 937-528-2900
- E-Mail: clinical.trials@daytonncorp.org
-
Hauptermittler:
- Tarek M. Sabagh
-
Franklin, Ohio, Vereinigte Staaten, 45005
- Suspendiert
- Dayton Physicians LLC-Atrium
-
Greenville, Ohio, Vereinigte Staaten, 45331
- Rekrutierung
- Miami Valley Cancer Care and Infusion
-
Hauptermittler:
- Tarek M. Sabagh
-
Kontakt:
- Site Public Contact
- Telefonnummer: 937-569-7515
-
Grove City, Ohio, Vereinigte Staaten, 43123
- Rekrutierung
- Zangmeister Center Grove City
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-488-2745
- E-Mail: Jeffh@columbusccop.org
-
Hauptermittler:
- Aruna C. Gowda
-
Kettering, Ohio, Vereinigte Staaten, 45429
- Rekrutierung
- Kettering Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 937-528-2900
- E-Mail: clinical.trials@daytonncorp.org
-
Hauptermittler:
- Howard M. Gross
-
Kettering, Ohio, Vereinigte Staaten, 45409
- Suspendiert
- Greater Dayton Cancer Center
-
Lancaster, Ohio, Vereinigte Staaten, 43130
- Rekrutierung
- Fairfield Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-488-2745
- E-Mail: Jeffh@columbusccop.org
-
Hauptermittler:
- Aruna C. Gowda
-
Mansfield, Ohio, Vereinigte Staaten, 44903
- Rekrutierung
- OhioHealth Mansfield Hospital
-
Hauptermittler:
- Aine E. Clements
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-788-3860
- E-Mail: Jennifer.Sexton@ohiohealth.com
-
Marion, Ohio, Vereinigte Staaten, 43302
- Rekrutierung
- OhioHealth Marion General Hospital
-
Hauptermittler:
- Aine E. Clements
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-788-3860
- E-Mail: Jennifer.Sexton@ohiohealth.com
-
Marysville, Ohio, Vereinigte Staaten, 43040
- Rekrutierung
- Memorial Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-488-2745
- E-Mail: Jeffh@columbusccop.org
-
Hauptermittler:
- Aruna C. Gowda
-
Mayfield Heights, Ohio, Vereinigte Staaten, 44124
- Aktiv, nicht rekrutierend
- Hillcrest Hospital Cancer Center
-
Mentor, Ohio, Vereinigte Staaten, 44060
- Rekrutierung
- UH Seidman Cancer Center at Lake Health Mentor Campus
-
Hauptermittler:
- Alberto J. Montero
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-641-2422
- E-Mail: CTUReferral@UHhospitals.org
-
Middleburg Heights, Ohio, Vereinigte Staaten, 44130
- Aktiv, nicht rekrutierend
- UH Seidman Cancer Center at Southwest General Hospital
-
Mount Vernon, Ohio, Vereinigte Staaten, 43050
- Rekrutierung
- Knox Community Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-488-2745
- E-Mail: Jeffh@columbusccop.org
-
Hauptermittler:
- Aruna C. Gowda
-
Newark, Ohio, Vereinigte Staaten, 43055
- Rekrutierung
- Licking Memorial Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-488-2745
- E-Mail: Jeffh@columbusccop.org
-
Hauptermittler:
- Aruna C. Gowda
-
Perrysburg, Ohio, Vereinigte Staaten, 43551
- Rekrutierung
- Mercy Health - Perrysburg Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-488-2745
- E-Mail: Jeffh@columbusccop.org
-
Hauptermittler:
- Aruna C. Gowda
-
Pickerington, Ohio, Vereinigte Staaten, 43147
- Rekrutierung
- OhioHealth Pickerington Methodist Hospital
-
Hauptermittler:
- Aine E. Clements
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-788-3860
- E-Mail: Jennifer.Sexton@ohiohealth.com
-
Portsmouth, Ohio, Vereinigte Staaten, 45662
- Rekrutierung
- Southern Ohio Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-488-2745
- E-Mail: Jeffh@columbusccop.org
-
Hauptermittler:
- Aruna C. Gowda
-
Springfield, Ohio, Vereinigte Staaten, 45504
- Rekrutierung
- Springfield Regional Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-488-2745
- E-Mail: Jeffh@columbusccop.org
-
Hauptermittler:
- Aruna C. Gowda
-
Springfield, Ohio, Vereinigte Staaten, 45504
- Rekrutierung
- Springfield Regional Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-488-2745
- E-Mail: Jeffh@columbusccop.org
-
Hauptermittler:
- Aruna C. Gowda
-
Toledo, Ohio, Vereinigte Staaten, 43623
- Rekrutierung
- Mercy Health - Saint Anne Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-488-2745
- E-Mail: Jeffh@columbusccop.org
-
Hauptermittler:
- Aruna C. Gowda
-
Toledo, Ohio, Vereinigte Staaten, 43623
- Suspendiert
- Toledo Clinic Cancer Centers-Toledo
-
Troy, Ohio, Vereinigte Staaten, 45373
- Rekrutierung
- Upper Valley Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 937-528-2900
- E-Mail: clinical.trials@daytonncorp.org
-
Hauptermittler:
- Tarek M. Sabagh
-
Westerville, Ohio, Vereinigte Staaten, 43081
- Rekrutierung
- Saint Ann's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-488-2745
- E-Mail: Jeffh@columbusccop.org
-
Hauptermittler:
- Aruna C. Gowda
-
Westerville, Ohio, Vereinigte Staaten, 43082
- Rekrutierung
- OhioHealth Westerville Medical Campus/Westerville Cancer Center
-
Hauptermittler:
- Aine E. Clements
-
Kontakt:
- Site Public Contact
- Telefonnummer: 610-788-3860
- E-Mail: Jennifer.Sexton@ohiohealth.com
-
Youngstown, Ohio, Vereinigte Staaten, 44501
- Suspendiert
- Saint Elizabeth Youngstown Hospital
-
Zanesville, Ohio, Vereinigte Staaten, 43701
- Rekrutierung
- Genesis Healthcare System Cancer Care Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-488-2745
- E-Mail: Jeffh@columbusccop.org
-
Hauptermittler:
- Aruna C. Gowda
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- Rekrutierung
- University of Oklahoma Health Sciences Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 405-271-8777
- E-Mail: ou-clinical-trials@ouhsc.edu
-
Hauptermittler:
- Lauren E. Dockery
-
-
Oregon
-
Newberg, Oregon, Vereinigte Staaten, 97132
- Rekrutierung
- Providence Newberg Medical Center
-
Hauptermittler:
- Alison K. Conlin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 503-215-2614
- E-Mail: CanRsrchStudies@providence.org
-
Ontario, Oregon, Vereinigte Staaten, 97914
- Rekrutierung
- Saint Alphonsus Cancer Care Center-Ontario
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Oregon City, Oregon, Vereinigte Staaten, 97045
- Rekrutierung
- Providence Willamette Falls Medical Center
-
Hauptermittler:
- Alison K. Conlin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 503-215-2614
- E-Mail: CanRsrchStudies@providence.org
-
Portland, Oregon, Vereinigte Staaten, 97239
- Rekrutierung
- Oregon Health and Science University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 503-494-1080
- E-Mail: trials@ohsu.edu
-
Hauptermittler:
- Christopher W. Ryan
-
Portland, Oregon, Vereinigte Staaten, 97213
- Rekrutierung
- Providence Portland Medical Center
-
Hauptermittler:
- Alison K. Conlin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 503-215-2614
- E-Mail: CanRsrchStudies@providence.org
-
Portland, Oregon, Vereinigte Staaten, 97225
- Rekrutierung
- Providence Saint Vincent Medical Center
-
Hauptermittler:
- Alison K. Conlin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 503-215-2614
- E-Mail: CanRsrchStudies@providence.org
-
-
Pennsylvania
-
Allentown, Pennsylvania, Vereinigte Staaten, 18103
- Rekrutierung
- Lehigh Valley Hospital-Cedar Crest
-
Kontakt:
- Site Public Contact
- Telefonnummer: 610-402-9543
- E-Mail: Morgan_M.Horton@lvhn.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Altoona, Pennsylvania, Vereinigte Staaten, 16601
- Rekrutierung
- UPMC Altoona
-
Kontakt:
- Site Public Contact
- E-Mail: ecog.rss@jimmy.harvard.edu
-
Hauptermittler:
- Adam M. Brufsky
-
Bethlehem, Pennsylvania, Vereinigte Staaten, 18017
- Rekrutierung
- Lehigh Valley Hospital - Muhlenberg
-
Kontakt:
- Site Public Contact
- Telefonnummer: 610-402-9543
- E-Mail: Morgan_M.Horton@lvhn.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Bryn Mawr, Pennsylvania, Vereinigte Staaten, 19010
- Rekrutierung
- Bryn Mawr Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 484-476-2649
- E-Mail: turzoe@mlhs.org
-
Hauptermittler:
- Paul B. Gilman
-
East Stroudsburg, Pennsylvania, Vereinigte Staaten, 18301
- Rekrutierung
- Pocono Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 610-402-9543
- E-Mail: Morgan_M.Horton@lvhn.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Erie, Pennsylvania, Vereinigte Staaten, 16505
- Rekrutierung
- UPMC Hillman Cancer Center Erie
-
Hauptermittler:
- Adam M. Brufsky
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-864-7716
- E-Mail: ClinicalResearchServices@upmc.edu
-
Greensburg, Pennsylvania, Vereinigte Staaten, 15601
- Rekrutierung
- UPMC Cancer Centers - Arnold Palmer Pavilion
-
Kontakt:
- Site Public Contact
- Telefonnummer: 724-838-1900
-
Hauptermittler:
- Adam M. Brufsky
-
Hazleton, Pennsylvania, Vereinigte Staaten, 18201
- Rekrutierung
- Lehigh Valley Hospital-Hazleton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 610-402-9543
- E-Mail: Morgan_M.Horton@lvhn.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Mechanicsburg, Pennsylvania, Vereinigte Staaten, 17050
- Rekrutierung
- UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-389-5208
- E-Mail: haneydl@upmc.edu
-
Hauptermittler:
- Adam M. Brufsky
-
Media, Pennsylvania, Vereinigte Staaten, 19063
- Rekrutierung
- Riddle Memorial Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 484-476-2649
- E-Mail: turzoe@mlhs.org
-
Hauptermittler:
- Paul B. Gilman
-
Monroeville, Pennsylvania, Vereinigte Staaten, 15146
- Rekrutierung
- UPMC Hillman Cancer Center - Monroeville
-
Hauptermittler:
- Adam M. Brufsky
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-864-7716
- E-Mail: ClinicalResearchServices@upmc.edu
-
Paoli, Pennsylvania, Vereinigte Staaten, 19301
- Rekrutierung
- Paoli Memorial Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 484-476-2649
- E-Mail: turzoe@mlhs.org
-
Hauptermittler:
- Paul B. Gilman
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19107
- Rekrutierung
- Thomas Jefferson University Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 215-600-9151
- E-Mail: ONCTrialNow@jefferson.edu
-
Hauptermittler:
- Jennifer M. Johnson
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19107
- Rekrutierung
- Pennsylvania Hospital
-
Hauptermittler:
- Mark S. Diamond
-
Kontakt:
- Site Public Contact
- Telefonnummer: 215-349-8245
- E-Mail: PMCancerResearch@pennmedicine.upenn.edu
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19111
- Rekrutierung
- Fox Chase Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 215-728-4790
-
Hauptermittler:
- Angela Jain
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15213
- Rekrutierung
- UPMC-Magee Womens Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-647-2811
-
Hauptermittler:
- Adam M. Brufsky
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15237
- Rekrutierung
- UPMC-Passavant Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-367-6454
-
Hauptermittler:
- Adam M. Brufsky
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15232
- Rekrutierung
- UPMC Hillman Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-647-8073
-
Hauptermittler:
- Adam M. Brufsky
-
Sayre, Pennsylvania, Vereinigte Staaten, 18840
- Rekrutierung
- Guthrie Medical Group PC-Robert Packer Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-836-0388
-
Hauptermittler:
- Joyson Poulose
-
Willow Grove, Pennsylvania, Vereinigte Staaten, 19090
- Rekrutierung
- Asplundh Cancer Pavilion
-
Kontakt:
- Site Public Contact
- Telefonnummer: 215-600-9151
- E-Mail: ONCTrialNow@jefferson.edu
-
Hauptermittler:
- Jennifer M. Johnson
-
Wynnewood, Pennsylvania, Vereinigte Staaten, 19096
- Rekrutierung
- Lankenau Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 484-476-2649
- E-Mail: turzoe@mlhs.org
-
Hauptermittler:
- Paul B. Gilman
-
-
Rhode Island
-
Providence, Rhode Island, Vereinigte Staaten, 02905
- Rekrutierung
- Women and Infants Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 401-274-1122
-
Hauptermittler:
- Paul A. DiSilvestro
-
Providence, Rhode Island, Vereinigte Staaten, 02908
- Rekrutierung
- Roger Williams Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 401-456-2698
- E-Mail: fdallesandro@chartercare.org
-
Hauptermittler:
- Ritesh Rathore
-
-
South Carolina
-
Boiling Springs, South Carolina, Vereinigte Staaten, 29316
- Rekrutierung
- Prisma Health Cancer Institute - Spartanburg
-
Hauptermittler:
- Ki Y. Chung
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
Columbia, South Carolina, Vereinigte Staaten, 29203
- Rekrutierung
- Prisma Health Richland Hospital
-
Hauptermittler:
- Ki Y. Chung
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
Easley, South Carolina, Vereinigte Staaten, 29640
- Rekrutierung
- Prisma Health Cancer Institute - Easley
-
Hauptermittler:
- Ki Y. Chung
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Vereinigte Staaten, 29605
- Rekrutierung
- BI-LO Charities Children's Cancer Center
-
Hauptermittler:
- Ki Y. Chung
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Vereinigte Staaten, 29601
- Rekrutierung
- Saint Francis Hospital
-
Hauptermittler:
- Stephen H. Dyar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-603-6234
- E-Mail: Heather_Rich@bshsi.org
-
Greenville, South Carolina, Vereinigte Staaten, 29605
- Rekrutierung
- Prisma Health Cancer Institute - Faris
-
Hauptermittler:
- Ki Y. Chung
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Vereinigte Staaten, 29607
- Rekrutierung
- Saint Francis Cancer Center
-
Hauptermittler:
- Stephen H. Dyar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-603-6234
- E-Mail: Heather_Rich@bshsi.org
-
Greenville, South Carolina, Vereinigte Staaten, 29605
- Rekrutierung
- Prisma Health Cancer Institute - Butternut
-
Hauptermittler:
- Ki Y. Chung
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Vereinigte Staaten, 29615
- Rekrutierung
- Prisma Health Cancer Institute - Eastside
-
Hauptermittler:
- Ki Y. Chung
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
Greer, South Carolina, Vereinigte Staaten, 29650
- Rekrutierung
- Prisma Health Cancer Institute - Greer
-
Hauptermittler:
- Ki Y. Chung
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
Seneca, South Carolina, Vereinigte Staaten, 29672
- Rekrutierung
- Prisma Health Cancer Institute - Seneca
-
Hauptermittler:
- Ki Y. Chung
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Rapid City, South Dakota, Vereinigte Staaten, 57701
- Aktiv, nicht rekrutierend
- Rapid City Regional Hospital
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57104
- Rekrutierung
- Sanford Cancer Center Oncology Clinic
-
Hauptermittler:
- Daniel Almquist
-
Kontakt:
- Site Public Contact
- Telefonnummer: 605-312-3320
- E-Mail: OncologyClinicTrialsSF@sanfordhealth.org
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57117-5134
- Rekrutierung
- Sanford USD Medical Center - Sioux Falls
-
Hauptermittler:
- Daniel Almquist
-
Kontakt:
- Site Public Contact
- Telefonnummer: 605-312-3320
- E-Mail: OncologyClinicalTrialsSF@SanfordHealth.org
-
-
Tennessee
-
Collierville, Tennessee, Vereinigte Staaten, 38017
- Rekrutierung
- Baptist Memorial Hospital and Cancer Center-Collierville
-
Kontakt:
- Site Public Contact
- Telefonnummer: 901-226-1366
- E-Mail: BCCclintrials@bmhcc.org
-
Hauptermittler:
- Andrew J. Benefield
-
Johnson City, Tennessee, Vereinigte Staaten, 37604
- Rekrutierung
- Regional Cancer Center at Johnson City Medical Center
-
Hauptermittler:
- Asheesh Shipstone
-
Kontakt:
- Site Public Contact
- Telefonnummer: 423-431-5654
- E-Mail: charles.mays@balladhealth.org
-
Kingsport, Tennessee, Vereinigte Staaten, 37660
- Rekrutierung
- Ballad Health Cancer Care - Kingsport
-
Hauptermittler:
- Asheesh Shipstone
-
Kontakt:
- Site Public Contact
- Telefonnummer: 423-431-5654
- E-Mail: charles.mays@balladhealth.org
-
Memphis, Tennessee, Vereinigte Staaten, 38120
- Rekrutierung
- Baptist Memorial Hospital and Cancer Center-Memphis
-
Kontakt:
- Site Public Contact
- Telefonnummer: 901-226-1366
- E-Mail: BCCclintrials@bmhcc.org
-
Hauptermittler:
- Andrew J. Benefield
-
Nashville, Tennessee, Vereinigte Staaten, 37232
- Rekrutierung
- Vanderbilt University/Ingram Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-811-8480
-
Hauptermittler:
- Jennifer H. Choe
-
Nashville, Tennessee, Vereinigte Staaten, 37204
- Rekrutierung
- Vanderbilt Breast Center at One Hundred Oaks
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-811-8480
-
Hauptermittler:
- Jennifer H. Choe
-
-
Texas
-
Abilene, Texas, Vereinigte Staaten, 79601
- Rekrutierung
- Hendrick Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 325-670-6340
-
Hauptermittler:
- Jose C. Velasco Di Domenico
-
Dallas, Texas, Vereinigte Staaten, 75390
- Rekrutierung
- UT Southwestern/Simmons Cancer Center-Dallas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 214-648-7097
- E-Mail: canceranswerline@UTSouthwestern.edu
-
Hauptermittler:
- Devin E. Jones
-
Houston, Texas, Vereinigte Staaten, 77030
- Aktiv, nicht rekrutierend
- Houston Methodist Hospital
-
Houston, Texas, Vereinigte Staaten, 77026-1967
- Rekrutierung
- Lyndon Baines Johnson General Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 713-566-5000
-
Hauptermittler:
- Funda Meric-Bernstam
-
Houston, Texas, Vereinigte Staaten, 77030
- Rekrutierung
- UT MD Anderson Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 866-632-6789
- E-Mail: askmdanderson@mdanderson.org
-
Hauptermittler:
- Funda Meric-Bernstam
-
Houston, Texas, Vereinigte Staaten, 77070
- Aktiv, nicht rekrutierend
- Methodist Willowbrook Hospital
-
Houston, Texas, Vereinigte Staaten, 77094
- Aktiv, nicht rekrutierend
- Houston Methodist West Hospital
-
Lubbock, Texas, Vereinigte Staaten, 79410
- Aktiv, nicht rekrutierend
- Covenant Medical Center-Lakeside
-
Nassau Bay, Texas, Vereinigte Staaten, 77058
- Aktiv, nicht rekrutierend
- Houston Methodist Saint John Hospital
-
Sugar Land, Texas, Vereinigte Staaten, 77479
- Aktiv, nicht rekrutierend
- Houston Methodist Sugar Land Hospital
-
Temple, Texas, Vereinigte Staaten, 76508
- Rekrutierung
- Scott and White Memorial Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 254-724-5407
-
Hauptermittler:
- Lucas Wong
-
The Woodlands, Texas, Vereinigte Staaten, 77385
- Aktiv, nicht rekrutierend
- Houston Methodist The Woodlands Hospital
-
-
Virginia
-
Bristol, Virginia, Vereinigte Staaten, 24201
- Rekrutierung
- Ballad Health Cancer Care - Bristol
-
Hauptermittler:
- Asheesh Shipstone
-
Kontakt:
- Site Public Contact
- Telefonnummer: 423-431-5654
- E-Mail: charles.mays@balladhealth.org
-
Charlottesville, Virginia, Vereinigte Staaten, 22908
- Rekrutierung
- University of Virginia Cancer Center
-
Hauptermittler:
- Matthew J. Reilley
-
Kontakt:
- Site Public Contact
- Telefonnummer: 434-243-6303
- E-Mail: uvacancertrials@hscmail.mcc.virginia.edu
-
Fairfax, Virginia, Vereinigte Staaten, 22031
- Rekrutierung
- Inova Schar Cancer Institute
-
Hauptermittler:
- Timothy L. Cannon
-
Kontakt:
- Site Public Contact
- Telefonnummer: 703-720-5210
- E-Mail: Stephanie.VanBebber@inova.org
-
Falls Church, Virginia, Vereinigte Staaten, 22042
- Rekrutierung
- Inova Fairfax Hospital
-
Hauptermittler:
- Timothy L. Cannon
-
Kontakt:
- Site Public Contact
- Telefonnummer: 703-208-6650
- E-Mail: Stephanie.VanBebber@inova.org
-
Richmond, Virginia, Vereinigte Staaten, 23235
- Rekrutierung
- VCU Massey Cancer Center at Stony Point
-
Kontakt:
- Site Public Contact
- E-Mail: ctoclinops@vcu.edu
-
Hauptermittler:
- Andrew Poklepovic
-
Richmond, Virginia, Vereinigte Staaten, 23229
- Aktiv, nicht rekrutierend
- Virginia Cancer Institute
-
Richmond, Virginia, Vereinigte Staaten, 23229
- Rekrutierung
- Henrico Doctor's Hospital
-
Hauptermittler:
- Andrew S. Kennedy
-
Kontakt:
- Site Public Contact
- Telefonnummer: 804-591-4152
-
Richmond, Virginia, Vereinigte Staaten, 23298
- Rekrutierung
- VCU Massey Comprehensive Cancer Center
-
Hauptermittler:
- Andrew Poklepovic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 804-628-6430
- E-Mail: CTOclinops@vcu.edu
-
Roanoke, Virginia, Vereinigte Staaten, 24033
- Rekrutierung
- Carilion Roanoke Memorial Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 540-985-8510
-
Hauptermittler:
- Andrew Poklepovic
-
South Hill, Virginia, Vereinigte Staaten, 23970
- Rekrutierung
- VCU Community Memorial Health Center
-
Kontakt:
- Site Public Contact
- E-Mail: nemer.elmouallem@vcuhealth.org
-
Hauptermittler:
- Andrew Poklepovic
-
-
Washington
-
Edmonds, Washington, Vereinigte Staaten, 98026
- Rekrutierung
- Swedish Cancer Institute-Edmonds
-
Hauptermittler:
- Alison K. Conlin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 206-215-2343
- E-Mail: PCRC-NCORP@Swedish.org
-
Issaquah, Washington, Vereinigte Staaten, 98029
- Rekrutierung
- Swedish Cancer Institute-Issaquah
-
Hauptermittler:
- Alison K. Conlin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 206-215-2343
- E-Mail: PCRC-NCORP@Swedish.org
-
Lacey, Washington, Vereinigte Staaten, 98503
- Rekrutierung
- Providence Regional Cancer System-Lacey
-
Hauptermittler:
- Alison K. Conlin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 360-412-8958
- E-Mail: deidre.dillon@providence.org
-
Renton, Washington, Vereinigte Staaten, 98055
- Rekrutierung
- Valley Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 425-228-3440
- E-Mail: research@valleymed.org
-
Hauptermittler:
- Khawaja S. Jahangir
-
Seattle, Washington, Vereinigte Staaten, 98122
- Rekrutierung
- Swedish Medical Center-First Hill
-
Hauptermittler:
- Alison K. Conlin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 206-215-2343
- E-Mail: PCRC-NCORP@Swedish.org
-
Walla Walla, Washington, Vereinigte Staaten, 99362
- Rekrutierung
- Providence Saint Mary Regional Cancer Center
-
Hauptermittler:
- Alison K. Conlin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 509-897-5993
- E-Mail: Cheryl.Dodd@providence.org
-
Yakima, Washington, Vereinigte Staaten, 98902
- Rekrutierung
- North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 509-574-3535
- E-Mail: Memorial-ClinicalTrials@yvmh.org
-
Hauptermittler:
- Khawaja S. Jahangir
-
-
West Virginia
-
Charleston, West Virginia, Vereinigte Staaten, 25304
- Rekrutierung
- Vandalia Health/CAMC Institute for Academic Medicine
-
Hauptermittler:
- Ahmed A. Khalid
-
Kontakt:
- Site Public Contact
- Telefonnummer: 304-388-9944
- E-Mail: CAMCClinicalTrials@vandaliahealth.org
-
Huntington, West Virginia, Vereinigte Staaten, 25701
- Rekrutierung
- Edwards Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 304-399-6566
- E-Mail: Christina.Cole@chhi.org
-
Hauptermittler:
- Toni O. Pacioles
-
Morgantown, West Virginia, Vereinigte Staaten, 26506
- Rekrutierung
- West Virginia University Healthcare
-
Kontakt:
- Site Public Contact
- Telefonnummer: 304-293-7374
- E-Mail: cancertrialsinfo@hsc.wvu.edu
-
Hauptermittler:
- Mohammed Almubarak
-
-
Wisconsin
-
Appleton, Wisconsin, Vereinigte Staaten, 54911
- Rekrutierung
- ThedaCare Regional Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-364-3604
- E-Mail: ResearchDept@thedacare.org
-
Hauptermittler:
- Matthias Weiss
-
Appleton, Wisconsin, Vereinigte Staaten, 54911
- Rekrutierung
- ThedaCare Regional Medical Center - Appleton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-364-3605
- E-Mail: ResearchDept@thedacare.org
-
Hauptermittler:
- Matthias Weiss
-
Ashland, Wisconsin, Vereinigte Staaten, 54806
- Rekrutierung
- Duluth Clinic Ashland
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-Mail: CancerTrials@EssentiaHealth.org
-
Hauptermittler:
- Bret E. Friday
-
Berlin, Wisconsin, Vereinigte Staaten, 54923
- Rekrutierung
- ThedaCare Cancer Care - Berlin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-364-3605
- E-Mail: ResearchDept@thedacare.org
-
Hauptermittler:
- Matthias Weiss
-
Burlington, Wisconsin, Vereinigte Staaten, 53105
- Rekrutierung
- Aurora Cancer Care-Southern Lakes VLCC
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Antony Ruggeri
-
Eau Claire, Wisconsin, Vereinigte Staaten, 54701
- Rekrutierung
- Marshfield Medical Center-EC Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-Mail: oncology.clinical.trials@marshfieldresearch.org
-
Hauptermittler:
- Adedayo A. Onitilo
-
Germantown, Wisconsin, Vereinigte Staaten, 53022
- Rekrutierung
- Aurora Health Care Germantown Health Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Antony Ruggeri
-
Grafton, Wisconsin, Vereinigte Staaten, 53024
- Rekrutierung
- Aurora Cancer Care-Grafton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Antony Ruggeri
-
Green Bay, Wisconsin, Vereinigte Staaten, 54311
- Rekrutierung
- Aurora BayCare Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Antony Ruggeri
-
Green Bay, Wisconsin, Vereinigte Staaten, 54301
- Rekrutierung
- Saint Vincent Hospital Cancer Center Green Bay
-
Hauptermittler:
- Brian L. Burnette
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-433-8889
- E-Mail: WI_research_admin@hshs.org
-
Green Bay, Wisconsin, Vereinigte Staaten, 54303
- Rekrutierung
- Saint Vincent Hospital Cancer Center at Saint Mary's
-
Hauptermittler:
- Brian L. Burnette
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-433-8889
- E-Mail: wi_research_admin@hshs.org
-
Janesville, Wisconsin, Vereinigte Staaten, 53548
- Rekrutierung
- Mercyhealth Hospital and Cancer Center - Janesville
-
Kontakt:
- Site Public Contact
- Telefonnummer: 608-756-6871
- E-Mail: oncologyclinicaltrials@mhemail.org
-
Hauptermittler:
- Emily G. Robinson
-
Kenosha, Wisconsin, Vereinigte Staaten, 53142
- Rekrutierung
- Aurora Cancer Care-Kenosha South
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Antony Ruggeri
-
La Crosse, Wisconsin, Vereinigte Staaten, 54601
- Rekrutierung
- Gundersen Lutheran Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 608-775-2385
- E-Mail: cancerctr@gundersenhealth.org
-
Hauptermittler:
- Kurt Oettel
-
Madison, Wisconsin, Vereinigte Staaten, 53792
- Rekrutierung
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Hauptermittler:
- Nataliya V. Uboha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-622-8922
- E-Mail: clinicaltrials@cancer.wisc.edu
-
Madison, Wisconsin, Vereinigte Staaten, 53718
- Rekrutierung
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Hauptermittler:
- Nataliya V. Uboha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-622-8922
- E-Mail: clinicaltrials@cancer.wisc.edu
-
Marinette, Wisconsin, Vereinigte Staaten, 54143
- Rekrutierung
- Aurora Bay Area Medical Group-Marinette
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Antony Ruggeri
-
Marshfield, Wisconsin, Vereinigte Staaten, 54449
- Rekrutierung
- Marshfield Medical Center-Marshfield
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-Mail: oncology.clinical.trials@marshfieldresearch.org
-
Hauptermittler:
- Adedayo A. Onitilo
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53209
- Rekrutierung
- Aurora Cancer Care-Milwaukee
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Antony Ruggeri
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53215
- Rekrutierung
- Aurora Saint Luke's Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Antony Ruggeri
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53233
- Rekrutierung
- Aurora Sinai Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Antony Ruggeri
-
Minocqua, Wisconsin, Vereinigte Staaten, 54548
- Rekrutierung
- Marshfield Medical Center - Minocqua
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-Mail: oncology.clinical.trials@marshfieldresearch.org
-
Hauptermittler:
- Adedayo A. Onitilo
-
Mukwonago, Wisconsin, Vereinigte Staaten, 53149
- Rekrutierung
- ProHealth D N Greenwald Center
-
Kontakt:
- Site Public Contact
- E-Mail: research.institute@phci.org
-
Hauptermittler:
- Timothy R. Wassenaar
-
Neenah, Wisconsin, Vereinigte Staaten, 54956
- Rekrutierung
- ThedaCare Regional Medical Center - Neenah
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-364-3605
- E-Mail: ResearchDept@thedacare.org
-
Hauptermittler:
- Matthias Weiss
-
New London, Wisconsin, Vereinigte Staaten, 54961
- Rekrutierung
- ThedaCare Cancer Care - New London
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-364-3605
- E-Mail: ResearchDept@thedacare.org
-
Hauptermittler:
- Matthias Weiss
-
New Richmond, Wisconsin, Vereinigte Staaten, 54017
- Rekrutierung
- Cancer Center of Western Wisconsin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Oconomowoc, Wisconsin, Vereinigte Staaten, 53066
- Rekrutierung
- ProHealth Oconomowoc Memorial Hospital
-
Hauptermittler:
- Timothy R. Wassenaar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 262-928-7878
-
Oconto Falls, Wisconsin, Vereinigte Staaten, 54154
- Rekrutierung
- Saint Vincent Hospital Cancer Center at Oconto Falls
-
Hauptermittler:
- Brian L. Burnette
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-433-8889
- E-Mail: WI_research_admin@hshs.org
-
Oshkosh, Wisconsin, Vereinigte Staaten, 54904
- Rekrutierung
- Vince Lombardi Cancer Clinic - Oshkosh
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Antony Ruggeri
-
Oshkosh, Wisconsin, Vereinigte Staaten, 54904
- Rekrutierung
- ThedaCare Cancer Care - Oshkosh
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-364-3605
- E-Mail: ResearchDept@thedacare.org
-
Hauptermittler:
- Matthias Weiss
-
Racine, Wisconsin, Vereinigte Staaten, 53406
- Rekrutierung
- Aurora Cancer Care-Racine
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Antony Ruggeri
-
Rice Lake, Wisconsin, Vereinigte Staaten, 54868
- Rekrutierung
- Marshfield Medical Center-Rice Lake
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-Mail: oncology.clinical.trials@marshfieldresearch.org
-
Hauptermittler:
- Adedayo A. Onitilo
-
Shawano, Wisconsin, Vereinigte Staaten, 54166
- Rekrutierung
- ThedaCare Cancer Care - Shawano
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-364-3605
- E-Mail: ResearchDept@thedacare.org
-
Hauptermittler:
- Matthias Weiss
-
Sheboygan, Wisconsin, Vereinigte Staaten, 53081
- Rekrutierung
- Vince Lombardi Cancer Clinic-Sheboygan
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Antony Ruggeri
-
Sheboygan, Wisconsin, Vereinigte Staaten, 53081
- Rekrutierung
- Saint Vincent Hospital Cancer Center at Sheboygan
-
Hauptermittler:
- Brian L. Burnette
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-433-8889
- E-Mail: wi_research_admin@hshs.org
-
Sheboygan, Wisconsin, Vereinigte Staaten, 53081
- Rekrutierung
- Sheboygan Physicians Group
-
Hauptermittler:
- Brian L. Burnette
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-433-8889
- E-Mail: wi_research_admin@hshs.org
-
Stevens Point, Wisconsin, Vereinigte Staaten, 54482
- Rekrutierung
- Marshfield Medical Center-River Region at Stevens Point
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-Mail: oncology.clinical.trials@marshfieldresearch.org
-
Hauptermittler:
- Adedayo A. Onitilo
-
Sturgeon Bay, Wisconsin, Vereinigte Staaten, 54235-1495
- Rekrutierung
- Saint Vincent Hospital Cancer Center at Sturgeon Bay
-
Hauptermittler:
- Brian L. Burnette
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-433-8889
- E-Mail: wi_research_admin@hshs.org
-
Summit, Wisconsin, Vereinigte Staaten, 53066
- Rekrutierung
- Aurora Medical Center in Summit
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Antony Ruggeri
-
Two Rivers, Wisconsin, Vereinigte Staaten, 54241
- Rekrutierung
- Vince Lombardi Cancer Clinic-Two Rivers
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Antony Ruggeri
-
Waukesha, Wisconsin, Vereinigte Staaten, 53188
- Rekrutierung
- UW Cancer Center at ProHealth Care
-
Hauptermittler:
- Timothy R. Wassenaar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 262-928-5539
- E-Mail: Chanda.miller@phci.org
-
Waupaca, Wisconsin, Vereinigte Staaten, 54981
- Rekrutierung
- ThedaCare Cancer Care - Waupaca
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-364-3605
- E-Mail: ResearchDept@thedacare.org
-
Hauptermittler:
- Matthias Weiss
-
Wauwatosa, Wisconsin, Vereinigte Staaten, 53226
- Rekrutierung
- Aurora Cancer Care-Milwaukee West
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Antony Ruggeri
-
West Allis, Wisconsin, Vereinigte Staaten, 53227
- Rekrutierung
- Aurora West Allis Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Antony Ruggeri
-
Weston, Wisconsin, Vereinigte Staaten, 54476
- Rekrutierung
- Marshfield Medical Center - Weston
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-Mail: oncology.clinical.trials@marshfieldresearch.org
-
Hauptermittler:
- Adedayo A. Onitilo
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Kind
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Patient must have measurable disease
-
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status between 0-2 OR patient must have Lansky performance status of >= 50% or Karnofsky performance status of >= 50%
-
Patient must be deemed potentially eligible for a ComboMATCH Treatment Trial as assessed by the enrolling provider
-
All patients must have sequencing results available from a National Cancer Institute (NCI) credentialed Designated Laboratory (DL)
-
Patients must have locally advanced or advanced histologically documented solid tumors requiring therapy and meet one of the following criteria:
- Patients must have progressed on at least one line of standard systemic therapy OR
- Patients whose disease has no standard treatment that has been shown to prolong overall survival
-
Patient must meet one of the following requirements:
-
Patients 18 years and older who have tumor amenable to minimal risk image-guided or direct vision biopsy and must be willing and able to undergo a tumor biopsy to obtain samples for research if the patient is to enroll in a ComboMATCH treatment trial OR
-
Patients 18 years and older who do not have disease that is biopsiable at minimal risk to the patient must confirm availability of an archival tumor tissue specimen for submission for research if the patient enrolls to a ComboMATCH Treatment Trial. This tumor tissue must meet the following criteria:
- Tissue must have been collected within 12 months prior to registration to the EAY191 Registration Trial
- Patient must not have had a Response Evaluation Criteria in Solid Tumors (RECIST) response (complete response [CR] or partial response [PR]) to any intervening therapy after collection of the tissue
- Formalin-fixed paraffin-embedded tumor tissue block(s) or slides must be available OR
-
Patients under 18 years old must confirm availability of an archival tumor tissue specimen for submission for research if patient enrolls to a ComboMATCH Treatment Trial. This tumor tissue must meet the following criteria:
- Formalin-fixed paraffin-embedded tumor tissue block(s) or slides must be available
-
NOTE: See specific ComboMATCH Treatment Trial protocol for tissue collection and management instructions. Performance of the mandatory research biopsy or submission of pre-trial formalin-fixed paraffin-embedded (FFPE) and collection and submission of the blood specimens for the integrated studies will be performed under the consent authority of the specific treatment trial protocol to which the patient is registered. No procedures to collect specimens for research only are to be performed for patients registered to the EAY191 Registration Trial only
-
-
NOTE: Each ComboMATCH Treatment Trial contains specific eligibility criteria. If patient is found to not be eligible for the assigned ComboMATCH Treatment Trial, indication of ineligibility will trigger re-evaluation and potential assignment to another Treatment Trial
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Screening
- Zuteilung: Zufällig
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: EAY191-A2 (Cohort 1, Arm A)
Cohort 1, Arm A: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression. |
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Undergo biopsy
Andere Namen:
Undergo PET
Andere Namen:
Given PO
Andere Namen:
Undergo bone scan
Andere Namen:
Undergo blood collection
Andere Namen:
Given PO
Andere Namen:
|
|
Experimental: EAY191-A2 (Cohort 2, Arm B)
Cohort 2, Arm B: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression. |
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Undergo biopsy
Andere Namen:
Undergo PET
Andere Namen:
Given PO
Andere Namen:
Undergo bone scan
Andere Namen:
Undergo blood collection
Andere Namen:
Given PO
Andere Namen:
|
|
Experimental: EAY191-A2 (Cohort 2, Arm C)
Cohort 2, Arm C: Patients receive olaparib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients experiencing disease progression have the option to migrate to Cohort 3, Arm D. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression. |
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Undergo biopsy
Andere Namen:
Undergo PET
Andere Namen:
Given PO
Andere Namen:
Undergo bone scan
Andere Namen:
Undergo blood collection
Andere Namen:
|
|
Experimental: EAY191-A2 (Cohort 3, Arm D)
Cohort 3, Arm D: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression. |
Undergo CT
Andere Namen:
Undergo biopsy
Andere Namen:
Undergo PET
Andere Namen:
Given PO
Andere Namen:
Undergo bone scan
Andere Namen:
Undergo blood collection
Andere Namen:
Given PO
Andere Namen:
|
|
Experimental: EAY191-A3 Combo Cohorts 1, 2, 3, 4 (palbociclib, binimetinib)
Patients receive palbociclib PO and binimetinib PO throughout the trial. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/or during follow up. |
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Undergo biopsy
Andere Namen:
Given PO
Andere Namen:
Undergo bone scan
Andere Namen:
Undergo blood collection
Andere Namen:
|
|
Experimental: EAY191-A3 Monotherapy Cohort 1 (binimetinib)
Patients receive binimetinib PO throughout the trial. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/or during follow up. |
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Undergo biopsy
Andere Namen:
Given PO
Andere Namen:
Undergo bone scan
Andere Namen:
Undergo blood collection
Andere Namen:
|
|
Experimental: EAY191-A6 Arm I (RAS/RAF/MEK/ERK mutations)
Patients receive leucovorin IV, oxaliplatin IV, and fluorouracil IV on study. Patients undergo ECHO and MUGA during screening and on study, a CT with contrast, MRI, or a FDG-PET during screening, collection of blood during screening and on study, and a biopsy during screening. Patients may also undergo brain MRI or CT during screening and on study, bone scans on study, and biopsy on study if clinically indicated. |
Given IV
Andere Namen:
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo biopsy
Andere Namen:
Undergo PET
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo bone scan
Andere Namen:
Undergo blood collection
Andere Namen:
|
|
Experimental: EAY191-A6 Arm II (RAS/RAF/MEK/ERK mutations)
Patients receive binimetinib PO, leucovorin IV, oxaliplatin IV, and fluorouracil IV on study. Patients undergo ECHO and MUGA during screening and on study, a CT with contrast, MRI, or an FDG-PET during screening, collection of blood during screening and on study, and a biopsy during screening. Patients may also undergo brain MRI or CT during screening and on study, bone scans on study, and biopsy on study if clinically indicated |
Given IV
Andere Namen:
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo PET
Andere Namen:
Given PO
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo bone scan
Andere Namen:
Undergo blood collection
Andere Namen:
|
|
Experimental: EAY191-E4 (taxane therapy)
Patients receive nilotinib hydrochloride monohydrate PO BID on days 1-28 and paclitaxel IV over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI during screening or cycle 1 day 1, every 2 cycles for 1 year, every 3 cycles for patients on study for more than 1 year, and every 4 cycles for patients on study for more than 3 years and may also undergo CT or MRI during follow-up every 3 months for 2 years and then every 6 months for 1 year if clinically indicated. Patients also undergo collection of blood samples at baseline, cycle 2 day 1, and optionally at progression as well as tumor biopsy at baseline and optionally at progression. |
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Undergo biopsy
Andere Namen:
Undergo blood collection
Andere Namen:
Given PO
Andere Namen:
Given PO or IV
Andere Namen:
|
|
Experimental: EAY191-E5 Cohort I Arm A (sotorasib, panitumumab)
Patients receive sotorasib PO QD on days 1-28 and panitumumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study. |
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Undergo biopsy
Andere Namen:
Given IV
Andere Namen:
Undergo blood collection
Andere Namen:
Given PO
Andere Namen:
|
|
Aktiver Komparator: EAY191-E5 Cohort I Arm B (sotorasib)
Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study. |
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Undergo biopsy
Andere Namen:
Undergo blood collection
Andere Namen:
Given PO
Andere Namen:
|
|
Experimental: EAY191-E5 Cohort II (sotorasib)
Patients receive combination therapy as in EAY191-E5 Arm A. |
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Undergo biopsy
Andere Namen:
Given IV
Andere Namen:
Undergo blood collection
Andere Namen:
Given PO
Andere Namen:
|
|
Experimental: EAY191-N2 Cohort I (Arm I) (NF1 mutations)
Patients receive fulvestrant IM on day 1 and day 15 of cycle 1 and day 1 of subsequent cycles and binimetinib PO BID on days 15 to 28 of cycle 1 and day 1 through 28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT, MRI, or bone scan, ECHO or MUGA, and tumor biopsy, as well as possible blood sample collection during screening and on study. |
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo biopsy
Andere Namen:
Given PO
Andere Namen:
Given IM
Andere Namen:
Undergo bone scan
Andere Namen:
Undergo blood collection
Andere Namen:
|
|
Experimental: EAY191-N2 Cohort I (Arm II) (NF1 mutations)
Patients receive fulvestrant IM on day 1 and day 15 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who progress on fulvestrant alone may migrate to cohort II if they meet the migration eligibility criteria. Patients not willing to migrate to cohort II will have further therapy at the investigator's discretion. Patients undergo a CT, MRI, or bone scan and tumor biopsy, as well as ECHO or MUGA and possible blood sample collection during screening and on study. |
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo biopsy
Andere Namen:
Given IM
Andere Namen:
Undergo bone scan
Andere Namen:
Undergo blood collection
Andere Namen:
|
|
Experimental: EAY191-N2 Cohort II (NF1 mutations)
Patients receive fulvestrant IM on day 1 of each cycle and binimetinib PO BID on days 15-28 of cycle 1 and day 1 through 28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT, MRI, or bone scan, ECHO or MUGA and tumor biopsy, as well as possible blood sample collection during screening and on study. |
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo biopsy
Andere Namen:
Given PO
Andere Namen:
Given IM
Andere Namen:
Undergo bone scan
Andere Namen:
Undergo blood collection
Andere Namen:
|
|
Experimental: EAY191-N4 Arm I (RAS pathway mutations)
Patients receive selumetinib PO BID and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as ECHO or MUGA, and CT scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated. |
Undergo bone marrow biopsy
Andere Namen:
Undergo CT
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo biopsy
Andere Namen:
Undergo bone marrow aspiration Given PO
Andere Namen:
Undergo blood collection
Andere Namen:
Undergo tumor mutational screening Given PO
Andere Namen:
|
|
Aktiver Komparator: EAY191-N4 Arm II (RAS pathway mutations)
Patients receive selumetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience progression may elect to cross over to Arm I provided they have not had dose limiting toxicities to monotherapy selumetinib. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as ECHO or MUGA, and CT scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated. |
Undergo bone marrow biopsy
Andere Namen:
Undergo CT
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo biopsy
Andere Namen:
Undergo bone marrow aspiration Undergo blood collection
Andere Namen:
Undergo tumor mutational screening Given PO
Andere Namen:
|
|
Aktiver Komparator: EAY191-N5 Arm I (neratinib maleate)
Patients receive neratinib maleate PO QD on days 1-14 of cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then receive neratinib maleate PO QD on days 1-28 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience progression may crossover to Arm II. Patients undergo ECHO or MUGA during screening and on study, and CT or MRI and collection of blood samples throughout the trial. Patients may also undergo tumor biopsy during screening and on study. |
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo biopsy
Andere Namen:
Undergo blood collection
Andere Namen:
Given PO
Andere Namen:
|
|
Experimental: EAY191-N5 Arm II (neratinib maleate,palbociclib)
Patients receive neratinib maleate PO QD on days 1-14 of cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then receive neratinib maleate PO QD on days 1-28 and palbociclib PO QD on days 1-21 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening and on study, and CT or MRI and collection of blood samples throughout the trial. Patients may also undergo tumor biopsy during screening and on study. |
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo biopsy
Andere Namen:
Given PO
Andere Namen:
Undergo blood collection
Andere Namen:
Given PO
Andere Namen:
|
|
Experimental: EAY191-S3 (activating AKT mutation)
Patients receive paclitaxel IV on days 1, 8, and 15 and ipatasertib PO on days 1-21 of each cycle. Treatment repeats every 28 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI and blood collection throughout the trial. Patients also undergo a tumor biopsy during screening and optionally during follow-up. |
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Undergo biopsy
Andere Namen:
Given PO
Andere Namen:
Undergo blood collection
Andere Namen:
Given PO or IV
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Accrual of patients to ComboMATCH treatment trials
Zeitfenster: Up to 8 years
|
Will be estimated over time and considered in relationship to changes in treatment trial cohort status (activations, suspensions, terminations). |
Up to 8 years
|
|
Assignment of patients to ComboMATCH treatment trials
Zeitfenster: Up to 8 years
|
Will be estimated over time and considered in relationship to changes in treatment trial cohort status (activations, suspensions, terminations). |
Up to 8 years
|
|
Enrollment rates to ComboMATCH treatment trials
Zeitfenster: Up to 8 years
|
Will be estimated over time and considered in relationship to changes in treatment trial cohort status (activations, suspensions, terminations). |
Up to 8 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Rate of positive outcomes within the treatment trial defined cohorts
Zeitfenster: Up to 8 years
|
For each cohort in each treatment trial there is a defined primary efficacy endpoint (usually progression free survival [PFS] or overall response rate) and defined primary analysis for evaluating the primary endpoint. As cohorts are completed, whether they meet the criteria for a positive primary outcome will be determined. Positive treatment cohort outcome (on primary endpoint) will be analyzed as a binary random variable. The raw proportion of treatment cohorts with positive outcomes and an exact binomial confidence interval will be computed. If there are a sufficient number of treatment cohorts, logistic regression analysis will be performed examining the relationship of treatment cohort characteristics with successful outcomes. The goal is to achieve a rate of at least 30% with positive outcomes, both overall and in the subset of treatment trials based on in vivo models. |
Up to 8 years
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Concordance between whole exome sequencing (WES) and results from the Designated Laboratory (DL)
Zeitfenster: Up to 8 years
|
Whole exome and other sequencing will be performed on mandatory tissue biopsies or, if no biopsy tissue is available, on submitted formalin-fixed paraffin-embedded tissue. These assays will be done in a clinical laboratory (e.g., Clinical Laboratory Improvement Act-compliant); but results will not be returned to the clinical site. Results will be used to compare with the DL assay results. This comparison will be required to conduct an important secondary analysis of the primary endpoint in each cohort in each treatment trial, restricting to those cases that are concordant between WES and the result from the DL that was the basis for enrollment (integrated). |
Up to 8 years
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: James M Ford, ECOG-ACRIN Cancer Research Group
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Genitalerkrankungen
- Erkrankungen des endokrinen Systems
- Pathologische Prozesse
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Neubildungen
- Weibliche Urogenitalerkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Uteruserkrankungen
- Genitalerkrankungen, weiblich
- Neoplasmen der endokrinen Drüse
- Neoplastische Prozesse
- Eierstockerkrankungen
- Adnexerkrankungen
- Genitale Neubildungen, weiblich
- Gonadenstörungen
- Uterusneoplasmen
- Eileitererkrankungen
- Pathologische Zustände, Anzeichen und Symptome
- Eierstocktumoren
- Neoplasma Metastasierung
- Endometriale Neubildungen
- Eileiterneoplasmen
- Hormone
- Hormone, Hormonersatzstoffe und Hormonantagonisten
- Aminosäuren, Peptide und Proteine
- Proteine
- Organische Chemikalien
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Untersuchungstechniken
- Klinische Labortechniken
- Diagnosetechniken und Verfahren
- Diagnose
- Chirurgische Eingriffe, operativ
- Zytologische Techniken
- Zytodiagnose
- Kohlenwasserstoffe
- Cycloparaffine
- Kohlenwasserstoffe, alicyclisch
- Kohlenwasserstoffe, zyklisch
- Terpene
- Polycyclische Verbindungen
- Enzyme und Coenzyme
- Antikörper, monoklonal, humanisiert
- Antikörper, monoklonal
- Antikörper
- Immunglobuline
- Immunoproteine
- Blutproteine
- Serumglobuline
- Globuline
- Koordinationskomplexe
- Taxoid
- Cyclodececane
- Diterpene
- Pyrimidine
- Steroide
- Fusions-Ring-Verbindungen
- Gesundheitsökonomie und Organisationen
- Diagnosetechniken, chirurgisch
- Chemie -Techniken, analytisch
- Spektrumanalyse
- Formyltetrahydrofolate
- Tetrahydrofolate
- Folsäure
- Pterins
- Pteridine
- Uracil
- Pyrimidinone
- Coenzyme
- Östradiol
- Estrenes
- Estranen
- Östradiol -Kongenere
- Gonadale Steroidhormone
- Gonadalhormone
- Wirtschaft
- Oxaliplatin
- Fulvestrant
- Panitumab
- Fluoruracil
- Leucovorin
- Paclitaxel
- Biopsie
- Handhabung von Proben
- Magnetresonanzspektroskopie
- Binimetinib
- ipatasertib
- Olaparib
- Palbociclib
- Nilotinib
- Dehydroftorafur
- Sotorasib
- Neratinib
- Alpelisib
- Steuern
Andere Studien-ID-Nummern
- NCI-2022-06842
- U10CA180820 (US NIH Stipendium/Vertrag)
- NCI-2022-06842 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- EAY191 (Andere Kennung: CTEP)
- EAY191 (Andere Kennung: ECOG-ACRIN Cancer Research Group)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .